SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 28, 2003
Commission File No. 1-15669
GENTIVA HEALTH SERVICES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 36-433-5801
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
3 Huntington Quadrangle 2S, Melville, New York 11747-8943
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (631) 501-7000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange on which registered
Common Stock, par value $.10 per NASDAQ
share
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X_ No __
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in PART III of this Form 10-K or any
amendment to this Form 10-K. [ ]
Indicate by check mark whether the registrant is an accelerated filer
(as defined in Exchange Act Rule 12b-2).
Yes X_ No __
The aggregate market value of the registrant's Common Stock held by
non-affiliates of the registrant as of June 27, 2003, the last business day of
registrant's most recently completed second fiscal quarter, was $225,337,941
based on the closing price of the Common Stock on the Nasdaq National Market on
such date.
The number of shares outstanding of the registrant's Common Stock, as
of February 26, 2004, was 25,528,593.
DOCUMENTS INCORPORATED BY REFERENCE
Certain information to be included in the registrant's definitive
Proxy Statement, to be filed not later than 120 days after the end of the fiscal
year covered by this Report, for the registrant's 2004 Annual Meeting of
Shareholders is incorporated by reference into PART III.
PART I
ITEM 1. BUSINESS
SPECIAL CAUTION REGARDING FORWARD-LOOKING STATEMENTS
CERTAIN STATEMENTS CONTAINED IN THIS ANNUAL REPORT ON FORM 10-K,
INCLUDING, WITHOUT LIMITATION, STATEMENTS CONTAINING THE WORDS "BELIEVES,"
"ANTICIPATES," "INTENDS," "EXPECTS," "ASSUMES," "TRENDS" AND SIMILAR
EXPRESSIONS, CONSTITUTE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE
BASED UPON THE COMPANY'S CURRENT PLANS, EXPECTATIONS AND PROJECTIONS ABOUT
FUTURE EVENTS. HOWEVER, SUCH STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS,
UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE
OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE
RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH
FORWARD-LOOKING STATEMENTS. SUCH FACTORS INCLUDE, AMONG OTHERS, THE FOLLOWING:
o GENERAL ECONOMIC AND BUSINESS CONDITIONS;
o DEMOGRAPHIC CHANGES;
o CHANGES IN, OR FAILURE TO COMPLY WITH, EXISTING GOVERNMENTAL
REGULATIONS;
o LEGISLATIVE PROPOSALS FOR HEALTH CARE REFORM;
o CHANGES IN MEDICARE AND MEDICAID REIMBURSEMENT LEVELS;
o EFFECTS OF COMPETITION IN THE MARKETS THE COMPANY OPERATES IN;
o LIABILITY AND OTHER CLAIMS ASSERTED AGAINST THE COMPANY;
o ABILITY TO ATTRACT AND RETAIN QUALIFIED PERSONNEL;
o AVAILABILITY AND TERMS OF CAPITAL;
o LOSS OF SIGNIFICANT CONTRACTS OR REDUCTION IN REVENUE ASSOCIATED
WITH MAJOR PAYOR SOURCES;
o ABILITY OF CUSTOMERS TO PAY FOR SERVICES;
o A MATERIAL SHIFT IN UTILIZATION WITHIN CAPITATED AGREEMENTS; AND
o CHANGES IN ESTIMATES AND JUDGMENTS ASSOCIATED WITH CRITICAL
ACCOUNTING POLICIES.
FOR A DETAILED DISCUSSION OF THESE AND OTHER FACTORS THAT COULD CAUSE
THE COMPANY'S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THE RESULTS CONTEMPLATED
BY THE FORWARD-LOOKING STATEMENTS, PLEASE REFER TO THE "RISK FACTORS" SECTION IN
THIS ITEM 1, TO "ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS" AND ELSEWHERE IN THIS REPORT. THE READER
SHOULD NOT PLACE UNDUE RELIANCE ON FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY
AS OF THE DATE OF THIS REPORT. EXCEPT AS REQUIRED UNDER THE FEDERAL SECURITIES
LAWS AND THE RULES AND REGULATIONS OF THE SECURITIES AND EXCHANGE COMMISSION
("SEC"), THE COMPANY DOES NOT HAVE ANY INTENTION OR OBLIGATION TO PUBLICLY
RELEASE ANY REVISIONS TO FORWARD-LOOKING STATEMENTS TO REFLECT UNFORESEEN OR
OTHER EVENTS AFTER THE DATE OF THIS REPORT. THE COMPANY HAS PROVIDED A DETAILED
DISCUSSION OF RISK FACTORS WITHIN THIS ANNUAL REPORT ON FORM 10-K AND VARIOUS
FILINGS WITH THE SEC. THE READER IS ENCOURAGED TO REVIEW THESE RISK FACTORS AND
FILINGS.
INTRODUCTION
Gentiva Health Services, Inc. ("Gentiva" or the "Company") provides
home health services throughout most of the United States. Gentiva was
incorporated in the state of Delaware on August 6, 1999 and became an
independent publicly owned company on March 15, 2000, when the common stock of
the Company was issued to the stockholders of Olsten Corporation, a Delaware
corporation ("Olsten"), the former parent corporation of the Company (the
"Split-Off"). Prior to the Split-Off, all of the assets and liabilities of
Olsten's health services business (formerly known as Olsten Health Services)
were transferred to the Company pursuant to a separation agreement and other
agreements among Gentiva, Olsten and Adecco SA ("Adecco").
On June 13, 2002, the Company sold substantially all of the assets of
its specialty pharmaceutical services ("SPS") business to Accredo Health,
Incorporated ("Accredo") and received payment of cash in the amount of $207.5
million (before a $0.9 million reduction resulting from a closing net book value
adjustment) and 5,060,976 shares of Accredo common stock (valued at $262.6
million, based on the closing price of Accredo common stock on the Nasdaq
National Market on June 13, 2002). The cash consideration (less a holdback of
$3.5 million for certain income taxes the Company expected to incur) and the
Accredo common stock were then distributed as a special dividend to the
Company's shareholders.
- 1 -
Information included in this annual report on Form 10-K refers to the
Company's continuing home health services business, unless the context indicates
otherwise.
HOME HEALTH SERVICES
The Company's home health services business is conducted through more
than 350 direct service delivery units and delivers a wide range of services
principally through its Gentiva(R) Health Services and CareCentrix(R) brands.
The Company operates licensed and Medicare-certified nursing agencies
located in 35 states, substantially all of which are currently accredited by the
Joint Commission on Accreditation of Healthcare Organizations (JCAHO). These
agencies provide various combinations of skilled nursing and therapy services,
paraprofessional nursing services and homemaker services to pediatric, adult and
elder patients. Reimbursement sources include government programs, such as
Medicare and Medicaid, and private sources, such as health insurance plans,
managed care organizations, long term care insurance plans and personal funds.
The Company's nursing operations are organized in five geographic regions, each
staffed with clinical, operational and sales teams. Regions are further
separated into operating areas. Each operating area includes branch locations
through which nursing agencies operate. Each agency is led by a director and is
staffed with clinical and administrative support staff as well as caregivers who
deliver direct patient care. The caregivers are employed on either a full-time
basis or are paid on a per visit, per shift, per diem or per hour basis.
The Company's CareCentrix operations provide an array of
administrative services and coordinate the delivery of home nursing services,
acute and chronic infusion therapies, durable medical equipment, and respiratory
products and services for managed care organizations and health plans. These
administrative services are coordinated within four regional coordination
centers and are delivered through the Company's nursing locations as well as
through an extensive nationwide network of third-party provider locations
credentialed by the Company (nearly 1,900 at December 28, 2003). CareCentrix
accepts case referrals from a wide variety of sources, verifies eligibility and
benefits and transfers case requirements to the credentialed providers for
services to the patient. CareCentrix provides services to its customers,
including the fulfillment of case requirements, care management, provider
credentialing, eligibility and benefits verification, data reporting and
analysis, and coordinated centralized billing for all authorized services
provided to the customer's enrollees. Contracts within CareCentrix are
structured as fee-for-service, whereby a payor is billed on a per usage basis
according to a fee schedule for various services, or as at-risk capitation,
whereby the payor remits a monthly payment to the Company based on the number of
members enrolled in the health plans under the capitation agreement, subject to
certain limitations and coverage guidelines.
The Company's home health services business also delivers services to
its customers through other focused business brands that include Gentiva
Orthopedic Services, a program which provides individualized home orthopedic
rehabilitation services to patients recovering from joint replacement or other
major orthopedic surgery, and Rehab Without Walls(R), which provides home and
community-based therapies for patients with traumatic brain injury,
cerebrovascular accident injury and acquired brain injury, as well as a number
of other complex rehabilitation cases. Other specialty services, including
therapies for patients with balance issues who are prone to injury or immobility
as a result of falling, are in various stages of development.
The Company also provides consulting services to home health agencies
through its Gentiva Business Services unit. These services include billing and
collection activities, web-based caregiver training and credentialing, on-site
agency support and consulting, operational support and individualized strategies
for reduction of days sales outstanding.
PAYORS
Net revenues attributable to major payor sources of reimbursement are
as follows:
FISCAL YEAR
----------------------------
2003 2002 2001
-------- -------- --------
Medicare 22% 21% 21%
Medicaid and Other Government 20 22 23
Commercial Insurance and Other 58 57 56
---- ---- ----
100% 100% 100%
==== ==== ====
- 2 -
The Company is party to a contract with CIGNA Health Corporation
("Cigna"), pursuant to which the Company provides or contracts with third party
providers to provide home nursing services, acute and chronic infusion
therapies, durable medical equipment, and respiratory products and services to
patients insured by Cigna. For fiscal years 2003, 2002 and 2001, Cigna accounted
for approximately 36 percent, 38 percent and 36 percent, respectively, of the
Company's net revenues.
The Company has extended its relationship with Cigna by entering into
a new national home health care contract effective January 1, 2004, with the new
contract expiring on December 31, 2006. No other commercial payor accounts for
10 percent or more of the Company's net revenues. Net revenues from commercial
payors are primarily generated under fee for service contracts which are
traditionally one year in term and renewable automatically on an annual basis,
unless terminated by either party.
TRADEMARKS
The Company has various trademarks registered with the U.S. Patent and
Trademark Office, including CARECENTRIX(R), GENTIVA(R), GENTIVA and Butterfly
Design(R) , LIFESMART(R) and REHAB WITHOUT WALLS(R), or otherwise in use by the
Company, including CASEMATCH(SM) and SAFE STRIDES(SM). A federally registered
trademark in the United States is effective for ten years subject only to a
required filing and the continued use of the mark by the Company, with the right
of perpetual renewal. A federally registered trademark provides the presumption
of ownership of the mark by the Company in connection with its goods or services
and constitutes constructive notice throughout the United States of such
ownership. Management believes that the Company's name and trademarks are
important to its operations and intends to continue to renew its trademark
registrations.
BUSINESS ENVIRONMENT
Factors that the Company believes have contributed and will contribute
to the development of home health services primarily include recognition that
home health services can be a cost-effective alternative to more expensive
institutional care; aging demographics; increasing consumer awareness and
interest in home health services; the psychological benefits of recuperating
from an illness or accident or receiving care for a chronic condition in one's
own home; and advanced technology that allows more health care procedures to be
provided at home.
The Company is actively pursuing relationships with managed care
organizations to secure additional managed care contracts. The Company believes
that its nationwide network of providers, financial resources, and the quality,
range and cost-effectiveness of its services are important factors as it seeks
opportunities in its managed care relationships in a consolidating home health
services industry. In addition, the Company believes that it has the local
relationships, the knowledge of the regional markets in which it operates, and
the cost-effective, comprehensive services and products required to compete
effectively for managed care contracts and other referrals. The Company offers
the direct and managed provision of care as a single source, which it believes
optimizes utilization.
MARKETING AND SALES
In general, the Company obtains patients and clients through personal
and corporate sales presentations, telephone marketing calls, direct mail
solicitation, referrals from other clients and advertising in a variety of local
and national media, including the Yellow Pages, newspapers, magazines, trade
publications and radio. The Company also maintains an Internet website
(www.gentiva.com) that describes the Company, its services and products.
Marketing efforts also involve personal contact with physicians, hospital
discharge planners, and case managers for managed health care programs, such as
those involving health maintenance organizations and preferred provider
organizations, insurance company representatives and employers with self-funded
employee health benefit programs.
COMPETITIVE POSITION
The home health services industry in which the Company operates is
highly competitive and fragmented. Home health care providers range from
facility-based (hospital, nursing home, rehabilitation facility, government
agency) agencies to independent companies to visiting nurse associations and
nurse registries. They can be not-for-profit organizations or for-profit
organizations. In addition, there are relatively few barriers to
- 3 -
entry in some of the home health services markets in which the Company operates.
The Company's primary competitors for its home health nursing business are
hospital-based home health agencies, local home health agencies and visiting
nurse associations. Based on information contained in the Center for Medicare
and Medicaid Services website, a government website containing information on
the home health care market in 2002, the Company believes its home health
services business holds approximately a 2 percent to 3 percent market share. The
Company competes with other home health care providers on the basis of
availability of personnel, quality and expertise of services and the value and
price of services. The Company believes that it has a favorable competitive
position, attributable mainly to its nationwide network of providers and the
consistently high quality and targeted services it has provided over the years
to its patients, as well as to its screening and evaluation procedures and
training programs for caregivers.
The Company expects that industry forces will impact it and its
competitors. The Company's competitors will likely strive to improve their
service offerings and price competitiveness. The Company also expects its
competitors to develop new strategic relationships with providers, referral
sources and payors, which could result in increased competition. The
introduction of new and enhanced services, acquisitions and industry
consolidation and the development of strategic relationships by the Company's
competitors could cause a decline in sales or loss of market acceptance of the
Company's services or price competition, or make the Company's services less
attractive.
SOURCE AND AVAILABILITY OF PERSONNEL
To maximize the cost effectiveness and productivity of caregivers, the
Company utilizes customized processes and procedures that have been developed
and refined over the years. Personalized matching to recruit and select
applicants who fit the patients' individual needs is achieved through initial
applicant profiles, personal interviews, skill evaluations and background and
reference checks. In 2003, the Company launched its proprietary CaseMatch(SM)
software scheduling program that gives local Company offices the ability to
identify instantly those caregivers who can be assigned to patient cases.
Caregivers are recruited through a variety of sources, including
advertising in local and national media, job fairs, solicitations on websites,
direct mail and telephone solicitations, as well as referrals obtained directly
from clients and other caregivers. Caregivers are generally paid on a per visit,
per shift, per hour or per diem basis, or are employed on a full-time salaried
basis. The Company, along with its competitors, is currently experiencing a
shortage of licensed professionals. A continued shortage of professionals could
have a material adverse effect on the Company's business.
NUMBER OF PERSONS EMPLOYED
At December 28, 2003, the Company had approximately 3,500 full-time
employees, including approximately 700 salaried caregivers. The Company also
employs caregivers on a temporary basis, as needed, to provide home health
services. In fiscal 2003, the average number of non-salaried caregivers employed
on a weekly basis in its home health services business was approximately 11,600.
The Company believes that its relationships with its employees are generally
good.
OTHER MATTERS
Subsequent to the sale of its specialty pharmaceutical services
business in June 2002, the Company has operated its remaining home health
services business as a single reporting unit. Financial information relating to
the home health services business is found in the consolidated financial
statements of the Company and its subsidiaries which are included in this annual
report.
The Company has historically experienced a seasonal decline in the
demand for its home health services during the third fiscal quarter.
For a discussion of certain regulations to which the Company's
business is subject, see "Regulations" under Item 3, "Legal Proceedings," below.
AVAILABLE INFORMATION
The Company's Internet address is www.gentiva.com. The Company makes
available free of charge on or through its Internet website its annual report on
Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and
amendments to those reports, filed or furnished pursuant to Section 13(a) or
15(d) of the
- 4 -
Securities Exchange Act of 1934, as soon as reasonably practicable after such
material has been filed with, or furnished to, the SEC. The Company also makes
available on or through its website its press releases, an investor
presentation, Section 16 reports and certain corporate governance documents.
RISK FACTORS
THIS ANNUAL REPORT ON FORM 10-K CONTAINS FORWARD-LOOKING STATEMENTS
WHICH INVOLVE A NUMBER OF RISKS, UNCERTAINTIES AND ASSUMPTIONS. ACTUAL RESULTS
COULD DIFFER MATERIALLY FROM THOSE DISCUSSED IN THE FORWARD-LOOKING STATEMENTS.
FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY INCLUDE, WITHOUT
LIMITATION, THE RISK FACTORS DISCUSSED BELOW AND ELSEWHERE IN THIS ANNUAL
REPORT.
RISKS RELATED TO THE COMPANY'S BUSINESS AND INDUSTRY
THE COMPANY'S GROWTH STRATEGY MAY NOT BE SUCCESSFUL.
The future growth of the Company's business and its future financial
performance will depend on, among other things, its ability to increase its
revenue base through a combination of internal growth and strategic ventures,
including acquisitions. The Company's home health services business experienced
no growth during the fiscal periods from 1998 through 2001. During fiscal 2002
and 2003, revenue from the Company's home health services business grew 5.3
percent and 5.9 percent, respectively; however, future revenue growth cannot be
assured as it is subject to the effects of competition, various risk factors
including the uncertainty of Medicare, Medicaid, and private health insurance
reimbursement, the ability to generate new and retain existing contracts with
major payor sources and the ability to attract and retain qualified personnel.
COMPETITION AMONG HOME HEALTH CARE COMPANIES IS INTENSE.
The home health services industry is highly competitive. The Company
competes with a variety of other companies in providing home health services,
some of which may have greater financial and other resources and may be more
established in their respective communities. Competing companies may offer newer
or different services from those offered by the Company and may thereby attract
customers who are presently receiving the Company's home health services.
THE COST OF HEALTH CARE IS FUNDED SUBSTANTIALLY BY GOVERNMENT AND
PRIVATE INSURANCE PROGRAMS. IF SUCH FUNDING IS REDUCED OR BECOMES
LIMITED OR UNAVAILABLE TO THE COMPANY'S CUSTOMERS, THE COMPANY'S
BUSINESS MAY BE ADVERSELY IMPACTED.
Third-party payors include Medicare, Medicaid and private health
insurance providers. Third-party payors are increasingly challenging prices
charged for health care services. The Company cannot be assured that its
services will be considered cost-effective by third-party payors, that
reimbursement will be available, or that payors' reimbursement policies will not
have a material adverse effect on the Company's ability to sell its services on
a profitable basis, if at all. The Company cannot control reimbursement rates or
policies for a significant portion of its business.
POSSIBLE CHANGES IN THE CASE MIX OF PATIENTS, AS WELL AS PAYOR MIX AND
PAYMENT METHODOLOGIES, MAY HAVE A MATERIAL ADVERSE EFFECT ON THE
COMPANY'S PROFITABILITY.
The sources and amounts of the Company's patient revenues will be
determined by a number of factors, including the mix of patients and the rates
of reimbursement among payors. Changes in the case mix of the patients as well
as payor mix among private pay, Medicare and Medicaid may significantly affect
the Company's profitability. In particular, any significant increase in the
Company's Medicaid population or decrease in Medicaid payments could have a
material adverse effect on its financial position, results of operations and
cash flow, especially if states operating these programs continue to limit, or
more aggressively seek limits on reimbursement rates or service levels.
THE LOSS OF SIGNIFICANT CONTRACTS, AS WELL AS SIGNIFICANT REDUCTIONS
IN MEMBERS COVERED UNDER SUCH CONTRACTS, COULD HAVE A MATERIAL ADVERSE
EFFECT ON THE COMPANY'S FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
The Company has entered into service agreements with a number of
managed care organizations to provide, or contracted with third party providers
to provide, home nursing services, acute and chronic infusion therapies, durable
medical equipment and respiratory products and services to patients insured by
those organizations. One such contract with Cigna accounted for 36 percent of
the Company's total net revenues for the year
- 5 -
ended December 28, 2003. The Company and Cigna entered into a new home health
care contract effective January 1, 2004 and expiring on December 31, 2006. Under
the termination provisions of the contract, Cigna has the right to terminate the
agreement on December 31, 2005, if it provides 90 days advance written notice to
the Company. If the Cigna contract or any other similar significant contract
were to terminate or if there was a significant decrease in enrolled members
covered under the Company's contract with Cigna or any other organization, it
could materially adversely affect the Company's financial condition and results
of operations.
FURTHER CONSOLIDATION OF MANAGED CARE ORGANIZATIONS AND OTHER
THIRD-PARTY PAYORS MAY ADVERSELY AFFECT THE COMPANY'S PROFITS.
Managed care organizations and other third-party payors have continued
to consolidate in order to enhance their ability to influence the delivery of
health care services. Consequently, the health care needs of a large percentage
of the United States population are increasingly served by a smaller number of
managed care organizations. These organizations generally enter into service
agreements with a limited number of providers for needed services. To the extent
that such organizations terminate the Company as a preferred provider and/or
engage its competitors as a preferred or exclusive provider, the Company's
business could be adversely affected. In addition, private payors, including
managed care payors, could seek to negotiate additional discounted fee
structures or the assumption by health care providers of all or a portion of the
financial risk through prepaid capitation arrangements, thereby potentially
reducing the Company's profitability.
THE COMPANY AND THE HEALTH CARE INDUSTRY CONTINUE TO EXPERIENCE
SHORTAGES IN QUALIFIED HOME HEALTH SERVICE CAREGIVERS.
The Company competes with other health care providers for its
employees. As the demand for home health services continues to exceed the supply
of available and qualified staff, the Company and its competitors have been
forced to offer more attractive wage and benefit packages to these
professionals. Furthermore, the competitive arena for this shrinking labor
market has created turnover as many seek to take advantage of the supply of
available positions, each offering new and more attractive wage and benefit
packages. In addition to the wage pressures inherent in this environment, the
cost of training new employees amid the turnover rates has caused added pressure
on the Company's operating margins.
AN ECONOMIC DOWNTURN, CONTINUED DEFICIT SPENDING BY THE FEDERAL
GOVERNMENT AND STATE BUDGET PRESSURES MAY RESULT IN A REDUCTION IN
REIMBURSEMENT AND COVERED SERVICES.
An economic downturn can have a detrimental effect on state revenues.
Historically, these budget pressures have translated into reductions in state
spending. Given that Medicaid outlays are a significant component of state
budgets, the Company can expect continuing cost containment pressures on
Medicaid outlays for the Company's services in the states in which it operates.
In addition, an economic downturn may also impact the number of enrollees in
managed care programs as well as the profitability of managed care companies,
which could result in reduced reimbursement rates.
Deficit spending by the government as the result of adverse
developments in the economy could lead to increased pressure to reduce
government expenditures for other purposes, including governmentally funded
programs in which the Company participates, such as Medicare and Medicaid.
THE AGREEMENT GOVERNING THE COMPANY'S EXISTING REVOLVING CREDIT
FACILITY CONTAINS, AND FUTURE DEBT AGREEMENTS MAY CONTAIN, VARIOUS
COVENANTS THAT LIMIT THE COMPANY'S DISCRETION IN THE OPERATION OF ITS
BUSINESS.
The agreement and instruments governing the Company's existing
revolving credit facility contain, and the agreements and instruments governing
its future debt agreements may contain, various restrictive covenants that,
among other things, require it to comply with or maintain certain financial
tests and ratios and restrict the Company's ability to:
o incur more debt;
o pay dividends, redeem stock or make other distributions;
o make certain investments;
o create liens;
o enter into transactions with affiliates;
o make acquisitions;
o merge or consolidate; and
- 6 -
o transfer or sell assets.
In addition, events beyond the Company's control could affect its
ability to comply with and maintain the financial tests and ratios. Any failure
by the Company to comply with or maintain all applicable financial tests and
ratios and to comply with all applicable covenants could result in an event of
default with respect to its existing revolving credit facility or future debt
agreements. This could lead to the acceleration of the maturity of the facility
and the termination of the commitments to make further extension of credit. The
Company has no outstanding debt as of December 28, 2003, but could incur debt in
the future. If the Company were unable to repay debt to its senior lenders,
these lenders could proceed against the collateral securing that debt. Even if
the Company is able to comply with all applicable covenants, the restrictions on
its ability to operate its business at its sole discretion could harm its
business by, among other things, limiting its ability to take advantage of
financing, mergers, acquisitions and other corporate opportunities.
THE COMPANY HAS RISKS RELATED TO OBLIGATIONS UNDER ITS INSURANCE
PROGRAMS.
The Company is obligated for certain costs under various insurance
programs, including employee health and welfare, workers compensation and
professional liability. The Company may be subject to workers compensation
claims and lawsuits alleging negligence or other similar legal claims. The
Company maintains various insurance programs to cover these risks but is
substantially self-insured for most of these claims. The Company also may be
subject to exposure relating to employment law and other related matters for
which the Company does not maintain insurance coverage. The Company believes
that its present insurance coverage and reserves are sufficient to cover
currently estimated exposures; however, there can be no assurance that the
Company will not incur liabilities in excess of recorded reserves or in excess
of its insurance limits.
THE COMPANY HAS RISKS RESULTING FROM THE SALE OF ITS SPS BUSINESS.
The Company has agreed to indemnify Accredo for losses suffered or
incurred by Accredo and its affiliates arising from the retained liabilities of
the Company, breaches of the Company's representations, warranties, covenants or
agreements under the asset purchase agreement between the Company and Accredo
dated January 2, 2002, or agreements delivered pursuant thereto, failure to
deliver good, valid and marketable title to the assets of the SPS business, and
specified tax liabilities of the Company, including those related to the
Company's Split-Off from Olsten. The liabilities retained by the Company include
litigation and causes of action arising prior to the closing of the sale of the
SPS business. These indemnification obligations are discussed in more detail
below under Item 3 "Legal Proceedings - Indemnifications." The Company is unable
to predict the amount, if any, that may be required for it to satisfy its
indemnification obligations under the asset purchase agreement should any claims
arise. Should any significant payment be required, the Company may not have
sufficient funds available to satisfy its potential indemnification obligations
or may not be able to obtain the funds on terms satisfactory to the Company, if
at all.
In addition, with the sale of the SPS business, the Company is no
longer able to deliver specialty pharmaceutical services, including the
distribution of chronic drugs and therapies and the provision of acute infusion
services, directly to payors and managed care providers, but will need to depend
fully on subcontracts with third parties, including Accredo. As a result, the
Company may be more susceptible to fluctuations in volume and in the prices it
pays to third parties for those services. These fluctuations in pricing may add
to the cost of providing the services and, as a result, adversely impact the
Company's profitability.
RISKS RELATED TO HEALTH CARE REGULATION
LEGISLATIVE AND REGULATORY ACTIONS RESULTING IN CHANGES IN
REIMBURSEMENT RATES OR METHODS OF PAYMENT FROM MEDICARE AND MEDICAID,
OR IMPLEMENTATION OF OTHER MEASURES TO REDUCE REIMBURSEMENT FOR THE
COMPANY'S SERVICES, MAY HAVE A MATERIAL ADVERSE EFFECT ON ITS REVENUES
AND OPERATING MARGINS.
In fiscal 2003, 42 percent of the Company's net revenues were
generated from Medicare, and Medicaid and Other Government programs. The health
care industry is experiencing a strong trend toward cost containment, as the
government seeks to impose lower reimbursement and utilization rates and
negotiate reduced payment schedules with providers. These cost containment
measures generally have resulted in reduced rates of reimbursement for services
that the Company provides.
In addition, the timing of payments made under these programs is
subject to regulatory action and governmental budgetary constraints. For certain
Medicaid programs, the time period between submission of claims and payment has
increased. Further, within the statutory framework of the Medicare and Medicaid
programs,
- 7 -
there are a substantial number of areas subject to administrative rulings and
interpretations that may further affect payments made under those programs.
Additionally, the federal and state governments may in the future reduce the
funds available under those programs or require more stringent utilization and
quality reviews of providers. Moreover, there can be no assurances that
adjustments from Medicare or Medicaid audits will not have a material adverse
effect on the Company.
The Benefits Improvement and Protection Act of 2000 mandates a phase
out of intergovernmental transfer transactions by states whereby states inflate
the payments to certain public facilities to increase federal matching funds.
This action may reduce federal support for a number of state Medicaid plans. The
reduced federal payments may adversely affect aggregate available funds, thereby
requiring states to reduce payments to all providers. The Company operates in
several of the states that will experience a contraction of federal matching
funds. With the repeal of the federal payment standards, there can be no
assurances that budget constraints or other factors will not cause states to
reduce Medicaid reimbursement or that payments will be made on a timely basis,
thereby adversely affecting payments made under these Medicaid programs.
THE COMPANY CONDUCTS BUSINESS IN A HEAVILY REGULATED INDUSTRY, AND
CHANGES IN REGULATIONS AND VIOLATIONS OF REGULATIONS MAY RESULT IN
INCREASED COSTS OR SANCTIONS.
The Company's business is subject to extensive federal, state and, in
some cases, local regulation. Compliance with these regulatory requirements, as
interpreted and amended from time to time, can increase operating costs or
reduce revenue and thereby adversely affect the financial viability of the
Company's business. Because these laws are amended from time to time and are
subject to interpretation, the Company cannot predict when and to what extent
liability may arise. Failure to comply with current or future regulatory
requirements could also result in the imposition of various remedies, including
fines, the revocation of licenses or decertification. Unanticipated increases in
operating costs or reductions in revenue could adversely affect the Company's
liquidity.
THE COMPANY IS SUBJECT TO PERIODIC AUDITS AND REQUESTS FOR INFORMATION
BY THE MEDICARE AND MEDICAID PROGRAMS OR GOVERNMENT AGENCIES, WHICH
HAVE VARIOUS RIGHTS AND REMEDIES AGAINST THE COMPANY IF THEY ASSERT
THAT THE COMPANY HAS OVERCHARGED THE PROGRAMS OR FAILED TO COMPLY WITH
PROGRAM REQUIREMENTS.
The operation of the Company's home health services business is
subject to federal and state laws prohibiting fraud by health care providers,
including laws containing criminal provisions, which prohibit filing false
claims or making false statements in order to receive payment or obtain
certification under Medicare and Medicaid programs, or failing to refund
overpayments or improper payments. Violation of these criminal provisions is a
felony punishable by imprisonment and/or fines. The Company may also be subject
to fines and treble damage claims if it violates the civil provisions that
prohibit knowingly filing a false claim or knowingly using false statements to
obtain payment. State and federal governments are devoting increased attention
and resources to anti-fraud initiatives against health care providers. The
Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and the
Balanced Budget Act of 1997 ("BBA") expanded the penalties for health care
fraud, including broader provisions for the exclusion of providers from the
Medicare and Medicaid programs.
The Company has established policies and procedures that it believes
are sufficient to ensure that it will operate in substantial compliance with
these anti-fraud and abuse requirements, including the Company's Corporate
Integrity Agreement. On April 17, 2003, the Company received a subpoena from the
Department of Health and Human Services, Office of the Inspector General, Office
of Investigations ("OIG"). The subpoena seeks information regarding the
Company's implementation of settlements and corporate integrity agreements
entered into with the government, as well as the Company's treatment on cost
reports of employees engaged in sales and marketing efforts. With respect to the
cost report issues, the government has preliminarily agreed to narrow the scope
of production to the period from January 1, 1998 through September 30, 2000. On
February 17, 2004, the Company received a subpoena from the U.S. Department of
Justice ("DOJ") seeking additional information related to the matters covered by
the OIG subpoena. The Company has provided documents and other information
requested by the OIG pursuant to its subpoena and similarly intends to cooperate
fully with the DOJ subpoena as well as any future OIG or DOJ information
requests. To the Company's knowledge, the government has not filed a complaint
against the Company. While the Company believes that its business practices are
consistent with Medicare and Medicaid programs criteria, those criteria are
often vague and subject to change and interpretation. The imposition of fines,
criminal penalties or program exclusions could have a material adverse effect on
the Company's financial condition, results of operations and cash flows.
- 8 -
THE COMPANY IS ALSO SUBJECT TO FEDERAL AND STATE LAWS THAT GOVERN
FINANCIAL AND OTHER ARRANGEMENTS BETWEEN HEALTH CARE PROVIDERS.
These laws often prohibit certain direct and indirect payments or
fee-splitting arrangements between health care providers that are designed to
encourage the referral of patients to a particular provider for medical products
and services. Furthermore, some states restrict certain business relationships
between physicians and other providers of health care services. Many states
prohibit business corporations from providing, or holding themselves out as a
provider of, medical care. Possible sanctions for violation of any of these
restrictions or prohibitions include loss of licensure or eligibility to
participate in reimbursement programs and civil and criminal penalties. These
laws vary from state to state, are often vague and have seldom been interpreted
by the courts or regulatory agencies.
THE COMPANY FACES ADDITIONAL FEDERAL REQUIREMENTS THAT MANDATE MAJOR
CHANGES IN THE TRANSMISSION AND RETENTION OF HEALTH INFORMATION.
HIPAA was enacted to ensure that employees can retain and at times
transfer their health insurance when they change jobs and to simplify health
care administrative processes. The enactment of HIPAA expanded protection of the
privacy and security of personal medical data and required the adoption of
standards for the exchange of electronic health information. Among the standards
that the Secretary of Health and Human Services has adopted pursuant to HIPAA
are standards for electronic transactions and code sets, unique identifiers for
providers, employers, health plans and individuals, security and electronic
signatures, privacy and enforcement. Although HIPAA was intended to ultimately
reduce administrative expenses and burdens faced within the health care
industry, the Company believes that implementation of this law will result in
additional costs. Failure to comply with HIPAA could result in fines and
penalties that could have a material adverse effect on the Company.
ITEM 2. PROPERTIES
The Company's headquarters is leased and is located at 3 Huntington
Quadrangle 2S, Melville, New York 11747-8943. Other major regional
administrative offices leased by the Company are located in Overland Park,
Kansas; Phoenix, Arizona; Hartford, Connecticut; Tampa, Florida; Endicott, New
York; and Houston, Texas. The Company also maintains leases for other offices
and locations on various terms expiring on various dates.
ITEM 3. LEGAL PROCEEDINGS
LITIGATION
In addition to the matters referenced in this Item 3, the Company is
party to certain legal actions arising in the ordinary course of business
including legal actions arising out of services rendered by its various
operations, personal injury and employment disputes.
COOPER V. GENTIVA CARECENTRIX, INC. t/a/d/b/a/ GENTIVA HEALTH
SERVICES, U.S. District Court (W.D. Penn), Civil Action No. 01-0508. On January
2, 2002, this amended complaint was served on the Company alleging that the
defendant submitted false claims to the government for payment in violation of
the Federal False Claims Act, 31 U.S.C. 3729 et seq., and that the defendant had
wrongfully terminated the plaintiff. The plaintiff claimed that infusion pumps
delivered to patients did not supply the full amount of medication, allegedly
resulting in substandard care. Based on a review of the court's docket sheet,
the plaintiff filed a complaint under seal in March 2001. In October 2001, the
United States government filed a notice with the court declining to intervene in
this matter, and on October 24, 2001, the court ordered that the seal be lifted.
The Company filed its responsive pleading on February 25, 2002, and discovery
has now commenced. The Company has denied the allegations of wrongdoing in the
complaint and is defending itself vigorously in this matter. On May 19, 2003,
the Company filed a motion for summary judgment on the issue of liability. On
February 6, 2004, the court granted partial summary judgment for the Company,
dismissing two of the three claims alleged under the False Claims Act and
denying summary judgment for the Company on the wrongful termination claim. The
parties are completing discovery; therefore, the Company cannot determine a
range of damages, if any, at this time.
- 9 -
GOVERNMENT MATTERS
On April 17, 2003, the Company received a subpoena from the Department
of Health and Human Services, Office of the Inspector General, Office of
Investigations ("OIG"). The subpoena seeks information regarding the Company's
implementation of settlements and corporate integrity agreements entered into
with the government, as well as the Company's treatment on cost reports of
employees engaged in sales and marketing efforts. With respect to the cost
report issues, the government has preliminarily agreed to narrow the scope of
production to the period from January 1, 1998 through September 30, 2000. On
February 17, 2004, the Company received a subpoena from the U.S. Department of
Justice ("DOJ") seeking additional information related to the matters covered by
the OIG subpoena. The Company has provided documents and other information
requested by the OIG pursuant to its subpoena and similarly intends to cooperate
fully with the DOJ subpoena as well as any future OIG or DOJ information
requests. To the Company's knowledge, the government has not filed a complaint
against the Company.
INDEMNIFICATIONS
In connection with the Split-Off, the Company agreed to assume, to the
extent permitted by law, and to indemnify Olsten for, the liabilities, if any,
arising out of the home health services business.
In addition, the Company and Accredo have agreed to indemnify each
other for breaches of representations and warranties of such party or the
non-fulfillment of any covenant or agreement of such party in connection with
the sale of the SPS business. The Company has also agreed to indemnify Accredo
for the retained liabilities and for tax liabilities, and Accredo has agreed to
indemnify the Company for assumed liabilities and the operation of the SPS
business after the closing of the acquisition. The representations and
warranties generally survive for the period of two years after the closing of
the acquisition, which occurred on June 13, 2002, except that:
o representations and warranties related to health care
compliance survive for three years after the closing of the
acquisition;
o representations and warranties related to title of the
assets and sufficiency of assets and employees survive for
the applicable statute of limitations period; and
o representations and warranties related to tax matters
survive until thirty days after the expiration of the
applicable tax statute of limitations period, including any
extensions of the applicable period, subject to certain
exceptions.
Accredo and the Company generally may recover indemnification for a
breach of a representation or warranty only to the extent a party's claim
exceeds $1 million for any individual claim, or exceeds $5 million in the
aggregate, subject to certain conditions and only up to a maximum amount of $100
million.
These indemnification rights are the exclusive remedy from and after
the closing of the acquisition, except for the right to seek specific
performance of any of the agreements in the related asset purchase agreement, in
any case where a party is guilty of fraud in connection with the acquisition,
and with respect to tax liabilities and obligations.
On May 6, 2003, the Company received correspondence from Accredo
giving the Company notice of Accredo's indemnification rights for any breach
under the asset purchase agreement related to the adequacy of the accounts
receivable reserves in accordance with section 8.3 of the asset purchase
agreement; however, no breach of a representation or warranty was asserted
against the Company in the correspondence.
CORPORATE INTEGRITY AGREEMENT
In connection with a July 19, 1999 settlement with various government
agencies, Olsten executed a corporate integrity agreement with the Office of
Inspector General of the Department of Health and Human Services, which will
remain in effect until August 18, 2004. The corporate integrity agreement
applies to the Company's businesses that bill the federal government health
programs directly for services, such as its nursing brand (but excludes the SPS
business), and focuses on issues and training related to cost report
preparation, contracting, medical necessity and billing of claims. Under the
corporate integrity agreement, the Company is required, for example, to maintain
a corporate compliance officer to develop and implement compliance programs, to
retain an independent review organization to perform annual reviews and to
maintain a compliance program and reporting systems, as well as to provide
certain training to employees.
- 10 -
The Company's compliance program is required to be implemented for all
newly established or acquired business units if their type of business is
covered by the corporate integrity agreement. Reports under the integrity
agreement are to be filed annually with the Department of Health and Human
Services, Office of Inspector General. After the corporate integrity agreement
expires, the Company is to file a final annual report with the government. The
Company is in compliance with the corporate integrity agreement and has timely
filed all required reports. If the Company fails to comply with the terms of its
corporate integrity agreement, the Company will be subject to penalties.
REGULATIONS
The Company's business is subject to extensive federal and state
regulations which govern, among other things:
o Medicare, Medicaid, TRICARE (the Department of Defense's managed
health care program for military personnel and their families)
and other government-funded reimbursement programs;
o reporting requirements, certification and licensing standards for
certain home health agencies; and
o in some cases, certificate-of-need requirements.
The Company's compliance with these regulations may affect its
participation in Medicare, Medicaid, TRICARE and other federal health care
programs. The Company is also subject to a variety of federal and state
regulations which prohibit fraud and abuse in the delivery of health care
services. These regulations include, among other things:
o prohibitions against the offering or making of direct or indirect
payments to actual or potential referral sources for obtaining or
influencing patient referrals;
o rules against physicians making referrals under Medicare for
clinical services to a home health agency with which the
physician or his or her immediate family member has certain types
of financial relationships;
o laws against the filing of false claims; and
o laws against making payment or offering items of value to
patients to induce their self-referral to the provider.
As part of the extensive federal and state regulation of the home
health services business and under the Company's corporate integrity agreement,
the Company is subject to periodic audits, examinations and investigations
conducted by, or at the direction of, governmental investigatory and oversight
agencies. Periodic and random audits conducted or directed by these agencies
could result in a delay in receipt, or an adjustment to the amount of
reimbursements due or received under Medicare, Medicaid, TRICARE and other
federal health programs. Violation of the applicable federal and state health
care regulations can result in excluding a health care provider from
participating in the Medicare, Medicaid and/or TRICARE programs and can subject
the provider to substantial civil and/or criminal penalties.
On October 1, 2002, the reduction in home health payment limits
mandated under the Balanced Budget Act of 1997 became effective. The change in
payment limits reduced payments under the Medicare program to home health
agencies for open episodes of care on or after October 1, 2002 by approximately
7 percent. Simultaneous with this reduction, market basket rate increases of 2.1
percent adjusted for certain wage indices were also implemented, resulting in an
overall reduction in reimbursement rates of approximately 4.9 percent. In
addition, Medicare reimbursement related to home health services performed in
specifically defined rural areas of the country was further reduced as the ten
percent rural add-on provision for home health services expired as of April 1,
2003. On October 1, 2003, a market basket rate increase of 3.3 percent became
effective for open episodes of care as of or after that date. The market basket
rate will be reduced 0.8 percent for open episodes of care on or after April 1,
2004. Furthermore, the Medicare reimbursement related to home health services
performed in specifically defined rural areas of the country will increase by 5
percent for a one year period, effective April 1, 2004.
- 11 -
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of security holders during the
fourth quarter of fiscal 2003.
EXECUTIVE OFFICERS OF THE COMPANY
The following table sets forth certain information regarding each of
the Company's executive officers as of February 26, 2004:
EXECUTIVE POSITION AND OFFICES
NAME OFFICER SINCE AGE WITH THE COMPANY
- ----------------------- ------------- --- ------------------------------------------
Ronald A. Malone 2000 49 Chief Executive Officer and Chairman of
the Board
Vernon A. Perry, Jr. 1999 52 President and Chief Operating Officer
Robert Creamer 2002 45 Senior Vice President, Nursing Operations,
and Chief Information Officer
Mary Morrisey Gabriel 2002 38 Senior Vice President, Sales
John R. Potapchuk 2001 51 Senior Vice President, Chief Financial
Officer, Treasurer and Secretary
Christopher L. Anderson 2001 32 Vice President, Audit Services and Quality
Assurance, and Chief Compliance Officer
Stephen B. Paige 2003 56 Vice President and General Counsel
The executive officers are elected annually by the board of directors.
RONALD A. MALONE
Mr. Malone has served as chief executive officer and chairman of the
board of the Company since June 2002. He served as executive vice president of
the Company from March 2000 to June 2002. Prior to joining the Company, he
served in various positions with Olsten, including executive vice president of
Olsten and president, Olsten Staffing Services, United States and Canada, from
January 1999 to March 2000. From 1994 to December 1998, he served successively
as Olsten's senior vice president, southeast division; senior vice president,
operations; and executive vice president, operations.
VERNON A. PERRY, JR.
Mr. Perry has served as president and chief operating officer of the
Company since June 2002. He served as senior vice president of the Company from
November 1999 to June 2002. From 1996 to 1999, he served as senior vice
president of CareCentrix for Olsten Health Services. He joined Olsten in 1994 as
vice president for business development.
ROBERT CREAMER
Mr. Creamer has served as senior vice president, nursing operations,
of the Company since September 2003 and as the Company's chief information
officer since June 2002. From June 2002 to August 2003, he served as senior vice
president, financial operations, of the Company. Prior thereto he served in
various corporate financial management positions with the Company and Olsten
Health Services, including vice president of finance-CareCentrix, vice president
of financial operations and vice president of finance - Specialty Pharmaceutical
Services. He first joined Olsten in 1991.
- 12 -
MARY MORRISEY GABRIEL
Ms. Morrisey Gabriel has served as senior vice president, sales, of
the Company since July 2002. From March 2000 to June 2002, Ms. Morrisey Gabriel
served as senior vice president of National Accounts/North American Sales of
Adecco, a staffing services company. From 1999 to March 2000, she served as
Olsten's senior vice president of national accounts.
JOHN R. POTAPCHUK
Mr. Potapchuk has served as senior vice president, chief financial
officer, treasurer and secretary of the Company since June 2002. He served as
vice president of finance and controller of the Company from March 2000 to June
2002. He joined Olsten in 1991 and served in various corporate financial
management positions with Olsten Health Services, including vice president and
operations controller and vice president of finance. Prior to that, Mr.
Potapchuk served in senior management positions for PricewaterhouseCoopers LLP
and Deloitte & Touche.
CHRISTOPHER L. ANDERSON
Mr. Anderson has served as the chief compliance officer and vice
president of audit services and quality assurance of the Company since March
2000. He served as chief compliance officer of Olsten from November 1998 to
March 2000.
STEPHEN B. PAIGE
Mr. Paige has served as vice president and general counsel of the
Company since July 2003. From 1997 to 2002, he served as senior vice president,
general counsel and secretary of General Semiconductor, Inc., a technology based
company. Prior thereto, Mr. Paige served in senior legal positions with several
large health care, food ingredient and consumer product companies.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
MARKET INFORMATION
The Company's common stock is quoted on the Nasdaq National Market
under the symbol "GTIV".
The following table sets forth the high and low bid information for
shares of the Company's common stock for each quarter during fiscal 2002 and
2003:
2002 (1) HIGH LOW
-------------------------------
1st Quarter $25.39 $20.65
2nd Quarter 27.55 7.90
3rd Quarter 9.29 6.72
4th Quarter 8.86 7.10
2003 HIGH LOW
-------------------------------
1st Quarter $10.34 $ 8.10
2nd Quarter 9.69 7.44
3rd Quarter 11.94 8.75
4th Quarter 13.59 10.98
(1) On June 13, 2002, the Company paid a special dividend to its
shareholders consisting of $7.76 cash and 0.19253 shares of Accredo
common stock per share of Gentiva common stock (valued at $9.99 per
- 13 -
share based on the June 13, 2002 closing price of $51.89 per share of
Accredo common stock) following the sale of the Company's SPS business
to Accredo. The total value of the special dividend amounted to $17.75
per share.
HOLDERS
As of February 26, 2004, there were approximately 2,300 holders of
record of the Company's common stock including participants in the Company's
employee stock purchase plan, brokerage firms holding the Company's common stock
in "street name" and other nominees.
DIVIDENDS
Except for the special dividend in cash ($7.76) and in kind (0.19253
shares of Accredo common stock) per share of Gentiva common stock paid in June
2002, the Company has never paid any cash dividends on its common stock. Any
future payments of dividends and the amount of the dividends will be determined
by the board of directors from time to time based on the Company's results of
operations, financial condition, cash requirements, future prospects and other
factors deemed relevant by the Company's board of directors, including any
substantive change in tax treatment under the United States Tax Code. In
addition, the Company's credit facility also contains restrictions on the
Company's ability to declare and pay dividends. See Item 7, "Management's
Discussion and Analysis of Financial Condition and Results of Operations."
ITEM 6. SELECTED FINANCIAL DATA
The following table provides selected historical consolidated
financial data of the Company as of and for each of the fiscal years in the
five-year period ended December 28, 2003. The data has been derived from the
Company's audited consolidated financial statements. The historical consolidated
financial information presents the Company's results of operations and financial
position as if the Company were a separate entity from Olsten for all years
presented.
In addition, the operating results of the SPS business through the
closing date of the sale to Accredo, including corporate expenses directly
attributable to SPS operations, restructuring and special charges related to the
SPS business, as well as the gain on the sale, net of transaction costs and
related income taxes, are reflected as discontinued operations in the
accompanying consolidated statements of operations. Continuing operations
includes the results of the home health services business, including corporate
expenses that did not directly relate to SPS, as well as restructuring and
special charges. In addition, for fiscal 2000 and 1999, continuing operations
included the health care staffing services business and Canadian operations
which were sold during the fourth quarter of fiscal 2000. Results of all prior
periods have been reclassified to conform to this presentation.
The historical financial information may not be indicative of the
Company's future performance and may not necessarily reflect what the financial
position and results of operations of the Company would have been if the Company
was a separate stand-alone entity during all the years presented.
- 14 -
(in thousands, except per share amounts) FISCAL YEAR ENDED
-----------------------------------------------------------------
2003 2002 2001 2000 1999
--------- --------- --------- --------- ---------
STATEMENT OF OPERATIONS DATA
Net revenues $ 814,029 $ 768,501 $ 729,577 $ 881,765 (8) $ 879,295 (8)
Gross profit 282,042 247,600 (2) 245,660 273,493 (4) 285,402
Selling, general and administrative expenses (259,185) (283,540)(2) (266,322)(3) (356,359)(4) (342,755)(5)
Income (loss) from continuing operations 56,766 (53,543) (13,910) (49,826) (41,077)
Discontinued operations, net of tax (6) - 191,578 34,898 (54,374)(4) 25,991
Cumulative effect of accounting change, net of tax (7) - (187,068) - - -
Net income (loss) 56,766(1) (49,033)(2) 20,988 (3) (104,200)(4) (15,086)(5)
Diluted earnings per share:
Income (loss) from continuing operations $ 2.07 $ (2.05) $ (0.60) $ (2.41) $ (2.02)
Discontinued operations, net of tax - 7.32 1.50 (2.64) 1.28
Cumulative effect of accounting change, net of tax - (7.14) - - -
Net income (loss) 2.07 (1.87) 0.90 (5.05) (0.74)
Weighted average shares outstanding - diluted 27,439 26,183 23,186 20,637 20,345 (9)
BALANCE SHEET DATA (AT END OF YEAR) (10)
Cash items and short-term investments (11) $ 110,013 $ 101,241 $ 107,144 $ 452 $ 2,942
Working capital 136,297 104,339 417,949 348,684 438,536
Total assets 335,088 264,431 849,879 805,484 1,063,015
Long-term debt and other securities - - - 20,000 78,562
Shareholders' equity 177,179 113,048 621,707 566,149 705,291
Common shares outstanding 25,598 26,385 25,639 21,197 20,345 (9)
SPECIAL DIVIDEND PER COMMON SHARE:
Cash - $ 7.76 - - -
Value of Accredo common stock - 9.99 - - -
(1) Net income for fiscal 2003 reflects a tax benefit of $35.0 million
associated with management's decision to reverse the valuation
allowance for deferred tax assets. See Notes 12 and 14 to the
Company's consolidated financial statements.
(2) Net loss in fiscal 2002 reflects restructuring and other special
charges aggregating $46.1 million, of which $6.3 million is recorded
in cost of services sold and $39.8 million is recorded in selling,
general and administrative expenses. See Note 4 to the Company's
consolidated financial statements.
(3) Net income in fiscal 2001 reflects special charges of approximately
$3.0 million in connection with the settlement of the GILE V. OLSTEN
CORPORATION, ET AL. and the STATE OF INDIANA V. QUANTUM HEALTH
RESOURCES, INC. AND OLSTEN HEALTH SERVICES, Inc. lawsuits and for
various other legal costs. These special charges are included in
selling, general and administrative expenses. See Note 4 to the
Company's consolidated financial statements.
(4) Net loss for fiscal 2000 reflects restructuring and other special
charges aggregating $153.2 million, of which $97.0 million related to
discontinued operations and $56.2 million related to continuing
operations. Restructuring and special charges of $8.5 million are
included in cost of services sold and $47.7 million is included in
selling, general and administrative expenses. Net loss for fiscal 2000
also reflects a gain of $36.7 million relating to the sale of the
Company's staffing services business and Canadian operations.
(5) Net loss for fiscal 1999 reflects a restructuring charge of $15.2
million for the realignment of business units as part of a new
restructuring plan. This charge is included in selling, general and
administrative expenses.
(6) For fiscal 2002, the Company sold its SPS business to Accredo in
accordance with the asset purchase agreement, dated January 2, 2002,
with the sale completed on June 13, 2002. As such, the Company has
reflected discontinued operations, including the gain on sale, of
$191.6 million during fiscal 2002. Results for all prior years have
been reclassified to conform to this presentation. See Note 3 to the
Company's consolidated financial statements.
(7) For fiscal 2002, the Company adopted the provisions of SFAS 142
"Goodwill and Other Intangible Assets" and performed a transitional
impairment test, resulting in a non-cash charge of $187.1 million. See
Note 2 to the Company's consolidated financial statements.
(8) Net revenues for fiscal 2000 and 1999 includes net revenues related to
the home health services business of $736.5 million and $727.2
million, respectively.
- 15 -
(9) Diluted earnings per share and the weighted average shares outstanding
for fiscal year 1999 and common shares outstanding at fiscal year end
1999 have been computed based on 20,345,029 shares of common stock.
Such amount is based on the number of shares of the Company's common
stock issued on March 15, 2000, the date of the split-off. See Note 1
to the Company's consolidated financial statements.
(10) Balance sheet data for fiscal year end 2001, 2000, and 1999 includes
the assets of the SPS business, which was sold to Accredo on June 13,
2002.
(11) Cash items and short-term investments includes restricted cash of
$21.8 million at fiscal year end 2003 and $35.2 million at fiscal year
end 2001.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion and analysis provides information which
management believes is relevant to an assessment and understanding of the
Company's results of operations and financial position. This discussion and
analysis should be read in conjunction with the Company's consolidated financial
statements and related notes included elsewhere in this report.
OVERVIEW
Gentiva is the nation's largest home health care company, based on the
amount of revenues derived from the provision of skilled home nursing services
to patients. The Company generates revenues and profits primarily by providing
patients with direct home health care services, including specialty services and
neuro-rehabilitation services; by delivering national, regional and local
administrative services to managed care organizations and self-insured
employers; and by providing home health care consulting services to independent
and hospital-based home health agencies.
Gentiva's direct home health services to patients include skilled
nursing; physical, occupational, speech and neuro-rehabilitation therapy
services; social work; nutrition; disease management education and help with
daily living activities, as well as other therapies and services. The Company's
specialty services involve physical therapist-led orthopedic rehabilitation
services for patients who have had joint replacements or other major orthopedic
surgery, as well as, commencing in 2003, therapies for patients with balance
issues who are prone to injury or immobility as a result of falling. Gentiva is
also piloting similar specialty programs for cardiopulmonary and wound care
services that are expected to be launched during 2004. The Company's
neuro-rehabilitation services, known as Rehab Without Walls(R), provide home and
community-based therapies for patients with traumatic brain injury,
cerebrovascular accident injury and acquired brain injury, as well as a number
of other complex rehabilitation cases.
Gentiva's national, regional and local administrative services for
managed care organizations and self-insured employers -- provided through its
CareCentrix(R) business unit -- include central access, care coordination,
utilization management, and claims processing. The Company is capable of
coordinating a wide range of home care services, including traditional home
nursing, chronic and acute infusion therapies, and durable medical and
respiratory equipment to member patients of these managed care organizations.
Consulting services to home health agencies are delivered primarily by
the Company's Gentiva Business Services unit. These services include billing and
collection activities, web-based caregiver training and credentialing, on-site
agency support and consulting, operational support, and individualized
strategies for reduction of days sales outstanding.
The Company's services can be delivered across the United States 24
hours a day, 7 days a week. Direct home health services to patients are
delivered through more than 350 owned and operated direct service delivery units
in approximately 250 locations in 35 states. Administrative services for managed
care organizations and self-insured employers are coordinated within four
regional coordination centers. Home care services provided to member patients of
these organizations are delivered through Company-owned and nearly 1,900
third-party credentialed provider locations covering the continental United
States.
Gentiva's revenues are generated primarily from three major payor
sources: the U.S. Medicare program, Medicaid and other state and county
programs, and commercial insurers. Revenue mix by major payor classifications
are as follows:
- 16 -
FISCAL YEAR
----------------------------
2003 2002 2001
-------- -------- --------
Medicare 22% 21% 21%
Medicaid and Other Government 20 22 23
Commercial Insurance and Other 58 57 56
---- ---- ----
100% 100% 100%
==== ==== ====
The Medicare and Medicaid and related programs are subject to
legislative and other risk factors that can result in fluctuating reimbursement
rates for Gentiva's direct home health services to patients. The commercial
insurance industry is continually seeking ways to control the cost of services
to patients that it covers. One of the ways it seeks to control costs is to
require greater efficiencies from its providers, including home health care
companies.
Despite these risks, Gentiva believes it can operate effectively in
the current health care climate by increasing its volume of Medicare and
commercial insurance business and implementing new business practices,
technologies and other methods to make the Company an even more efficient
provider of services. In fact, Gentiva has made a strategic decision to seek
more business from the Medicare and commercial insurance payor groups. For
example, in 2003, Gentiva's revenue from its Medicare and Commercial Insurance
and Other payor categories increased 10.1 percent and 7.2 percent, respectively,
from the prior year.
Various states have addressed budget pressures by considering or
implementing reductions in various health care programs, including reductions in
rates or changes in patient eligibility requirements. In addition, the Company
has also decided to taper participation in certain Medicaid and other state and
county programs. As a result, Gentiva's 2003 revenue from this payor category
declined 1.3 percent from the prior year.
Gentiva believes that several marketplace factors can contribute to
its future growth. First, the Company is a leader in a highly fragmented home
health care industry populated by approximately 12,000 providers of varying size
and resources. Second, the cost of a home health care visit to a patient can be
significantly lower than the cost of an average day in a hospital or skilled
nursing institution. And third, the demand for home care is expected to grow,
primarily due to an aging U.S. population. The U.S. Centers for Medicare and
Medicaid Services projects that national home health and durable medical
equipment spending will rise from $62.5 billion in 2004 to $103.7 billion by
2012. The U.S. Census Bureau has estimated that the age 65 and older population
will increase more than 50 percent between 2000 and 2020.
The Company expects to capitalize on these positive trends through a
determined set of strategies, as follows: generate balanced growth by focusing
on Medicare and Commercial Insurance business; continue to develop and expand
specialty services for incremental revenue growth; focus on caregiver
recruitment, retention and productivity; and launch technology initiatives that
make Gentiva more efficient and profitable. The Company anticipates executing
these strategies by continuing to expand its sales presence, developing and
marketing its managed care services, making operational improvements and
deploying new technologies, providing employees with leadership training and
instituting retention initiatives, ensuring strong ethics and corporate
governance, and focusing on shareholder value.
Results from these strategies and initiatives began to appear in the
Company's 2003 performance. Gentiva reported 2003 net revenue of $814.0 million,
representing a $45.5 million or 5.9 percent increase from the $768.5 million
reported in fiscal year 2002. The increase was due primarily to a rise in the
volume of Medicare and commercial insurance business mentioned above. Net income
for fiscal 2003 was $56.8 million, or $2.07 per diluted share, which included a
tax benefit of $1.28 per diluted share related to the reversal of a tax
valuation allowance discussed later in this annual report. This compares to a
loss of $49.0 million, or $1.87 per diluted share, including restructuring and
special charges, for the corresponding period of 2002.
During 2003, Gentiva reported positive cash flow from operating
activities of $30.7 million and increased its balance of cash items, restricted
cash and short-term investments at the end of the year to approximately $110
million, compared to approximately $101 million at the end of 2002. The Company
has previously stated that it would evaluate using its cash primarily for the
following purposes: investments contributing to revenue growth, efficiency and
profitability; selective acquisitions; share repurchases; and the possible
future payment of dividends to shareholders. In 2003, Gentiva repurchased a
total of over 1.4 million shares at an average cost of $10.03 per share, for a
total expenditure of over $14.4 million.
- 17 -
Management intends the discussion of the Company's financial condition
and results of operations that follows to provide information that will assist
in understanding the Company's financial statements, the changes in certain key
items in those financial statements from year to year, and the primary factors
that accounted for those changes, as well as how certain accounting principles,
policies and estimates affect its financial statements.
The historical results sections in "Results of Operations" below
present a discussion of the Company's consolidated operating results using the
historical results of Gentiva prepared in accordance with accounting principles
generally accepted in the United States (GAAP) for the fiscal years ended
December 28, 2003, December 29, 2002 and December 30, 2001.
SIGNIFICANT DEVELOPMENTS
On June 13, 2002, the Company sold substantially all of the assets of
its specialty pharmaceutical services ("SPS") business to Accredo Health,
Incorporated ("Accredo") and received payment of cash in the amount of $207.5
million (before a $0.9 million reduction resulting from a closing net book value
adjustment) and 5,060,976 shares of Accredo common stock (valued at $262.6
million, based on the closing price of Accredo common stock on the Nasdaq
National Market on June 13, 2002). The cash consideration, less a holdback of
$3.5 million for certain income taxes the Company expected to incur, and the
Accredo common stock were then distributed as a special dividend to the
Company's shareholders.
The operating results of the SPS business through the closing date of
the sale to Accredo, including corporate expenses directly attributable to SPS
operations, restructuring and special charges related to the SPS business, as
well as the gain on the sale, net of transaction costs and related income taxes,
are reflected as discontinued operations in the accompanying consolidated
statements of operations. Continuing operations includes the results of the home
health services business, including corporate expenses that did not directly
relate to SPS, as well as restructuring and special charges.
YEAR ENDED DECEMBER 28, 2003 COMPARED TO YEAR ENDED DECEMBER 29, 2002
RESULTS OF OPERATIONS
REVENUES
Net revenues increased by $45 million or 5.9 percent to $814 million
during fiscal 2003 as compared to $769 million during fiscal 2002. For fiscal
year 2003, as compared to fiscal year 2002, net revenues from Medicare increased
by $16.4 million or 10.1 percent to $178.7 million. Commercial Insurance and
Other payors net revenues increased by $31.4 million or 7.2 percent to $470.2
million and Medicaid and Other Government payors net revenues decreased $2.3
million or 1.3 percent to $165.2 million.
Medicare revenue growth for fiscal 2003, as compared to fiscal 2002,
was primarily fueled by increases in episodes serviced of 8.7 percent. In
addition, Medicare revenue was positively impacted by (i) $1.6 million due to a
3.3 percent market basket rate increase that became effective for patients on
service on or after October 1, 2003 and (ii) $2.5 million due to the absence of
a revenue adjustment recorded in fiscal 2002 relating to partial episode
payments ("PEPs") as well as various clinical and operational process changes
implemented in late 2003. In comparing the fiscal year 2003 and 2002 periods,
Medicare revenues were negatively impacted by an overall 4.9 percent reduction
in Medicare reimbursement rates (approximately $6.0 million for fiscal 2003),
which became effective for Medicare patients beginning in October 2002, and by
the elimination of the rural add-on provision ($1.4 million for fiscal 2003) for
home health services, which became effective April 1, 2003.
Revenue growth from Commercial Insurance and Other payors was driven
by a combination of pricing and volume increases from existing customers and new
contracts that were signed during the past year. Of the 7.2 percent increase in
net revenues for fiscal 2003, new contracts from Commercial Insurance and Other
payors accounted for 3.3 percent.
Medicaid and Other Government revenues decreased for fiscal year 2003
due to revenue reductions related to more restrictive eligibility requirements
in some states and lower reimbursement rates in certain other states. In
addition, for fiscal 2003, revenues were negatively impacted by the Company's
decision to reduce or terminate its participation in certain low-margin, hourly
Medicaid and state and county programs. Revenues relating to these hourly
Medicaid and state and county programs decreased $8.5 million as compared to
fiscal
- 18 -
year 2002. These decreases were offset somewhat by increases in the intermittent
care Medicaid business in selected states.
GROSS PROFIT
Gross profit was approximately $282 million for fiscal year 2003
compared to $248 million for fiscal year 2002. As a percentage of net revenues,
gross profit margins increased from 32.2 percent for fiscal year 2002 to 34.6
percent for fiscal year 2003.
Gross profit margins for fiscal 2003 as compared to fiscal 2002, were
positively impacted by an increase in Medicare episodes serviced and
improvements in utilization in both the commercial insurance business and
Medicare (1.6 percent), reductions in insurance costs (0.5 percent), the
Medicare market basket rate increase of 3.3 percent that became effective for
patients on service on or after October 1, 2003 (0.2 percent) and the absence of
both a $2.5 million revenue adjustment related to PEPs (0.3 percent) and the
$6.3 million special charge associated with insurance costs that were recorded
in fiscal 2002 (0.8 percent). These increases were partially offset by an
overall 4.9 percent reduction in Medicare reimbursement rates (approximately
$6.0 million or 0.8 percent), which became effective for Medicare patients
beginning October 2002, and the elimination of the rural add-on provision ($1.4
million or 0.2 percent) for home health services which became effective April 1,
2003.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
For fiscal year 2003, selling, general and administrative expenses,
including depreciation and amortization, decreased $24 million or 8.6 percent to
$259 million compared to $283 million for the corresponding period in fiscal
2002. This decrease is related to restructuring and special charges of $46.1
million, of which approximately $40 million was reflected in selling, general
and administrative expenses in the accompanying consolidated statement of
operations for fiscal year 2002. See Note 4 to the consolidated financial
statements for further discussion of the restructuring and special charges.
Excluding these special charges, selling, general and administrative expenses,
including depreciation and amortization, increased $15.4 million for fiscal year
2003.
This increase for fiscal 2003 related to increases in sales and field
administrative expenses due to headcount additions, investments in technology
initiatives and costs relating to training in connection with the implementation
of provisions of the Healthcare Insurance Portability and Accountability Act of
1996 ("HIPAA") and a new software based scheduling system. These increases were
partially offset by reductions in corporate administrative expenses resulting
from restructuring efforts following the sale of the SPS business in the second
quarter of fiscal year 2002. During fiscal 2003, headcount of personnel
dedicated to sales and clinical care coordination efforts increased by
approximately 19 percent while headcount relating to field and administrative
personnel increased by less than 2 percent.
Restructuring and special charges for fiscal year 2002 are summarized
and further described below (in thousands):
FISCAL YEAR ENDED
DECEMBER 29, 2002
-----------------
Restructuring charges:
Business realignment activities $ 6,813
--------
Special charges:
Option tender offer 21,388
Settlement costs 7,731
Insurance costs 6,300
Asset writedowns and other 3,824
--------
Total special charges 39,243
--------
Total restructuring and special charges $ 46,056
========
- 19 -
FISCAL 2002
BUSINESS REALIGNMENT ACTIVITIES
The Company recorded charges of $6.8 million during the second quarter
ended June 30, 2002 in connection with a restructuring plan. This plan included
the closing and consolidation of seven field locations and the realignment and
consolidation of certain corporate and administrative support functions due
primarily to the sale of the Company's SPS business. These charges included
employee severance of $0.9 million relating to the termination of 115 employees
in field locations and certain corporate and administrative departments, and
future lease payments and other associated costs of $5.9 million resulting
principally from the consolidation of office space at the Company's corporate
headquarters and a change in estimated future lease obligations and other costs
in excess of sublease rentals relating to a lease for a subsidiary of the
Company's former parent company which the Company agreed to assume in connection
with its Split-Off in March 2000. These charges are reflected in selling,
general and administrative expenses in the accompanying consolidated statement
of operations for the fiscal year ended December 29, 2002 During fiscal year
2002, the Company paid $2.1 million in restructuring costs, leaving
approximately $4.7 million of these restructuring charges unpaid, representing
severance costs of $0.2 million which were to be paid during 2003 and lease and
other associated costs of $4.5 million which will be paid over the remaining
lease terms. During fiscal year 2003, the Company paid $2.4 million in
restructuring costs, leaving approximately $2.3 million of these restructuring
charges unpaid, representing lease and other associated costs which will be paid
over the remaining lease terms.
OPTION TENDER OFFER
During the second quarter ended June 30, 2002, the Company effected a
cash tender offer for all outstanding options to purchase its common stock for
an aggregate option purchase price not to exceed $25 million. In connection with
this tender offer, the Company recorded a charge of $21.4 million during the
second quarter of fiscal 2002, which is reflected in selling, general and
administrative expenses in the accompanying consolidated statement of operations
for fiscal year 2002.
SETTLEMENT COSTS
The Company recorded a $7.7 million charge in the second quarter of
fiscal 2002 to reflect settlement costs relating to the FREDRICKSON V. OLSTEN
HEALTH SERVICES CORP. AND OLSTEN CORPORATION lawsuit as well as estimated
settlement costs related to government inquiries regarding cost reporting
procedures concerning contracted nursing and home health aide costs (see Note 9
to the consolidated financial statements). These costs are reflected in selling,
general and administrative costs in the accompanying consolidated statement of
operations for fiscal year 2002.
INSURANCE COSTS
The Company recorded a special charge of $6.3 million in the second
quarter of fiscal 2002 related primarily to a refinement in the estimation
process used to determine the Company's actuarially computed workers
compensation and professional liability insurance reserves. This special charge
is reflected in cost of services sold in the accompanying consolidated statement
of operations for fiscal year 2002.
ASSET WRITEDOWNS AND OTHER
The Company recorded charges of $3.8 million in the second quarter of
fiscal 2002, consisting primarily of a write-down of inventory and other assets
associated with home medical equipment used in the Company's nursing operations,
and a write-off of deferred debt issuance costs associated with the terminated
credit facility. The charges are reflected in selling, general and
administrative expenses in the accompanying consolidated statement of operations
for fiscal year 2002.
INTEREST INCOME, NET
Net interest income was approximately $0.4 million for fiscal year
2003 and $0.8 million for fiscal year 2002. Net interest income represented
interest income of approximately $1.5 million for fiscal 2003 and $2.4
- 20 -
million for fiscal 2002, partially offset by fees relating to the revolving
credit facility and outstanding letters of credit.
Interest income declined in fiscal 2003 as compared to fiscal 2002 due
to a decline in interest rates on cash, cash equivalents and restricted cash
and, to a lesser extent, a decrease in average cash balances during the year.
Interest expense declined in the fiscal 2003 periods due to reductions in the
average outstanding letters of credit, as well as reductions in fees associated
with the unused portion of the credit facility.
INCOME TAXES
The Company recorded an income tax benefit of $33.5 million in fiscal
2003 compared to an income tax expense of $18.4 million in fiscal 2002.
A federal and state tax benefit was recorded in fiscal 2002, relative
to the loss from continuing operations, offset by a $26.8 million provision
associated with the adoption of SFAS No. 142, as discussed in Note 2 to the
consolidated financial statements, and an adjustment of $5.4 million for tax
audit adjustments. As of December 29, 2002, the Company had federal net
operating loss and tax credit carryforwards of $15 million and maintained a full
valuation allowance against its net deferred tax assets of $63.9 million.
Realization of the deferred tax assets is dependent on generating sufficient
taxable income. During the interim periods of fiscal 2003, a portion of the
valuation allowance ($9.4 million) was utilized to offset a corresponding
decrease in net deferred tax assets. Based on management`s belief that it is
more likely than not that all of the Company's net deferred tax assets will be
realized due to the Company's achieved earnings trends and outlook, the
remaining valuation allowance for net deferred tax assets was reversed resulting
in a tax benefit of $35.0 million recorded in the statement of operations and an
additional credit of $19.5 million relating to the tax benefits associated with
stock compensation was recorded directly to shareholders' equity. At December
28, 2003, current net deferred tax assets were $26.5 million and non-current net
deferred tax assets were $28.0 million. At December 28, 2003, the Company had
federal net operating loss and tax credit carryforwards of $11.8 million. See
Note 12 to the Company's consolidated financial statements.
NET INCOME (LOSS)
The Company recorded net income of $56.8 million or $2.07 per diluted
share in fiscal 2003 compared to a net loss of $49.0 million or ($1.87) per
diluted share in fiscal 2002.
The net loss for fiscal 2002 included a net loss from continuing
operations of $53.5 million or ($2.05) per diluted share, which included $46.1
million of restructuring and special charges, income from discontinued
operations of $191.6 million or $7.32 per diluted share and a net charge of
$187.1 million or ($7.14) per diluted share relating to the cumulative effect of
accounting change for goodwill.
- 21 -
YEAR ENDED DECEMBER 29, 2002 COMPARED TO YEAR ENDED DECEMBER 30, 2001
RESULTS OF OPERATIONS
REVENUES
Net revenues increased by $39 million or 5.3 percent to $769 million
during fiscal 2002 as compared to $730 million during fiscal 2001. This increase
was driven by a combination of increased rates to Commercial Insurance and Other
and certain Medicaid and Other Government payors, increased volume in nursing
patient admissions and an increase in the number of Preferred Provider
Organization enrollees served by the Company's CareCentrix unit, partially
offset by a 4.9 percent net reduction in Medicare reimbursement rates, which
became effective in October 2002.
For fiscal year 2002, as compared to fiscal year 2001, net revenues
from Medicare increased by $9.7 million or 6.3 percent to $162.3 million.
Commercial Insurance and Other payors net revenues increased by $30 million or
7.3 percent to $438.8 million and Medicaid and Other Government payors net
revenues decreased $0.7 million or 0.4 percent to $167.4 million.
GROSS PROFIT
Gross profit was approximately $248 million for fiscal year 2002
compared to $246 million for fiscal year 2001. As a percentage of net revenues,
gross profit margins decreased from 33.7 percent for fiscal year 2001 to 32.2
percent for fiscal year 2002.
The decrease in margin was primarily related to a $6.3 million special
charge relating principally to a refinement in the estimation process used to
determine the Company's actuarially computed workers compensation and
professional liability insurance reserves (see Note 4 to the consolidated
financial statements). This special charge had a negative impact on gross profit
margins of 0.8 percent. In addition to the special charge, the Company also
recorded a revenue adjustment of $2.5 million, which had a 0.3 percent negative
impact on margins, related to a change in the estimated amount of the repayment
to Medicare for partial episode payments ("PEPs") from the inception of the
Prospective Payment System of reimbursement ("PPS") in October 2000 through June
30, 2002. The 4.9 percent net reduction in Medicare reimbursement rates, which
became effective in October 2002, had a negative impact of approximately $2.0
million, or 0.3 percent, on gross profit margins for fiscal year 2002. The
remaining net decrease in gross margin percentage was attributable to various
other factors, including training costs associated with orientation of
additional full-time caregivers, increased insurance costs and changes in
business mix due to growth in the CareCentrix business, which generates a lower
gross margin but also requires lower administrative costs to service the
business, offset by increased rates to Commercial Insurance and Other and
certain Medicaid and Other Government payors.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses increased $17 million or
6.5 percent to $283 million during fiscal 2002 compared to $266 million during
fiscal 2001. These increases were driven by restructuring and special charges of
$46.1 million during the second quarter ended June 30, 2002, of which
approximately $40 million was reflected in selling, general and administrative
expenses in the accompanying consolidated statement of operations for the fiscal
year ended December 29, 2002, as compared to $3 million of special charges which
were reflected in the consolidated statement of operations for the fiscal year
ended December 30, 2001. These net increases were offset by reductions in
amortization expense ($10 million) due to the implementation of SFAS No. 142 and
net reductions ($10 million) in field and corporate administration expenses as a
result of restructuring efforts and improvements in processes and technology,
partially offset by an increase in selling expenses.
- 22 -
FISCAL 2002
For a further discussion on restructuring and special charges for the
fiscal year ended December 29, 2002, see management's discussion above on
"Selling, General and Administrative Expenses" and "Fiscal 2002," under "Results
of Operations" for the "Year Ended December 28, 2003 Compared to Year Ended
December 29, 2002."
FISCAL 2001
SETTLEMENT COSTS
The Company recorded special charges of approximately $3.0 million
during fiscal 2001 in connection with the settlement of the GILE V. OLSTEN
CORPORATION, ET AL., and the STATE OF INDIANA V. QUANTUM HEALTH RESOURCES, INC.
AND OLSTEN HEALTH SERVICES, INC. lawsuits and for various other legal costs.
These legal matters are further discussed in Note 9 to the consolidated
financial statements. These special charges are reflected in selling, general
and administrative expenses in the accompanying consolidated statement of
operations for fiscal year 2001.
INTEREST EXPENSE, NET
Net interest income (expense) was approximately $0.8 million and
($0.1) million in fiscal 2002 and 2001, respectively. Net interest income for
fiscal 2002 primarily represented interest earned on investments of $2.4 million
offset by fees relating to the revolving credit facility and outstanding letters
of credit. Net interest expense for fiscal 2001 primarily represented fees
relating to the revolving credit facility and outstanding letters of credit and,
for the first half of fiscal 2001, the 10 percent convertible preferred trust
securities, which were redeemed in the third quarter of fiscal 2001, offset by
interest income of approximately $2.8 million.
INCOME TAXES
Income tax expense was $18.4 million in fiscal 2002 compared to an
income tax benefit of $6.8 million in fiscal 2001. A federal and state tax
benefit was recorded in fiscal 2002, relative to the loss from continuing
operations, offset by a $26.8 million provision associated with the adoption of
SFAS No. 142, as discussed in Note 2 to the consolidated financial statements,
and an adjustment of $5.4 million for tax audit adjustments. The Company had a
federal net operating loss carryforward at December 30, 2001 of $89.7 million
that was used in part to offset the gain from the sale of the SPS division. As
of December 29, 2002, the Company had a federal net operating loss carryforward
of $15 million. Net deferred tax assets were $63.9 million at December 29, 2002
and $27 million at December 30, 2001. The increase in deferred tax assets
relates primarily to the adoption of SFAS 142 offset by utilization of a portion
of the federal net operating loss during 2002. At December 29, 2002, the Company
had maintained a full valuation allowance against its net deferred tax asset.
Realization of the deferred tax asset is dependent on generating sufficient
taxable income. See Note 12 to the Company's consolidated financial statements.
NET INCOME (LOSS)
The Company recorded a net loss of $49.0 million or ($1.87) per
diluted share in fiscal 2002 compared to net income of $21.0 million or $0.90
per diluted share in fiscal 2001. The net loss for fiscal 2002 includes a net
loss from continuing operations of $53.5 million or ($2.05) per diluted share,
which included $46.1 million of restructuring and special charges, income from
discontinued operations of $191.6 million or $7.32 per diluted share and a net
charge of $187.1 million or ($7.14) per diluted share relating to the cumulative
effect of accounting change for goodwill. Net income for fiscal 2001 includes a
net loss from continuing operations of $13.9 million or ($0.60) per diluted
share, including special charges, and income from discontinued operations of
$34.9 million or $1.50 per diluted share.
- 23 -
LIQUIDITY AND CAPITAL RESOURCES
LIQUIDITY
The Company's principal source of liquidity is the collection of its
accounts receivable. For healthcare services, the Company grants credit without
collateral to its patients, most of whom are insured under third party
commercial or governmental payor arrangements. Net cash provided by operating
activities increased $12.2 million to $30.7 million in fiscal 2003. This cash
was used to fund capital expenditures of $8.8 million and repurchase shares of
common stock of $14.4 million during fiscal 2003.
Days Sales Outstanding ("DSO") for the home health services business
remained flat at 59 days at December 28, 2003 as compared to December 29, 2002.
Working capital at December 28, 2003 was $136 million, an increase of $32
million as compared to $104 million at December 29, 2002, primarily due to:
o a $9 million increase in cash and cash equivalents, restricted
cash and short-term investments;
o a $8 million increase in accounts receivable;
o a $26 million increase in deferred tax assets relating to the
Company's reversal of the deferred tax asset valuation allowance
as further described in Note 12 to the Company's consolidated
financial statements;
o a $3 million decrease in prepaid expenses and other assets; and
o a $7 million increase in current liabilities, primarily driven by
increases in other accrued expenses ($7 million), cost of claims
incurred but not reported ($1 million), and Medicare liabilities
($1 million), partially offset by a decrease in accounts payable
($1 million) and obligations under insurance programs ($1
million).
The Company participates in the Medicare, Medicaid and other federal
and state healthcare programs. There are certain standards and regulations that
the Company must adhere to in order to continue to participate in these
programs, including compliance with the Company's corporate integrity agreement.
As part of these standards and regulations, the Company is subject to periodic
audits, examinations and investigations conducted by, or at the direction of,
governmental investigatory and oversight agencies. Periodic and random audits
conducted or directed by these agencies could result in a delay or adjustment to
the amount of reimbursements received under these programs. Violation of the
applicable federal and state health care regulations can result in the Company's
exclusion from participating in these programs and can subject the Company to
substantial civil and/or criminal penalties. The Company believes it is
currently in compliance with these standards and regulations.
The Company is party to a contract with CIGNA Health Corporation
("Cigna"), pursuant to which the Company provides or contracts with third party
providers to provide home nursing services, acute and chronic infusion
therapies, durable medical equipment, and respiratory products and services to
patients insured by Cigna. For fiscal years 2003, 2002 and 2001, Cigna accounted
for approximately 36 percent, 38 percent and 36 percent, respectively, of the
Company's total net revenues. The Company has extended its relationship with
Cigna by entering into a new national home health care contract, effective
January 1, 2004. The term of the new contract extends to December 31, 2006, and
automatically renews thereafter for additional one year terms unless terminated.
Under the termination provisions, Cigna has the right to terminate the agreement
on December 31, 2005 if it provides 90 days advance written notice to the
Company, and each party has the right to terminate at the end of each term
thereafter by providing at least 90 days advance written notice prior to the
start of the new term. If Cigna chose to terminate or not renew the contract, or
to significantly modify its use of the Company's services, there could be a
material adverse effect on the Company's cash flow.
The Company's credit facility, which was entered into on June 13,
2002, as amended, as described below, provides up to $55 million in borrowings,
including up to $40 million which is available for letters of credit. The
Company may borrow up to a maximum of 80 percent of the net amount of eligible
accounts receivable, as defined, less any reasonable and customary reserves, as
defined, required by the lender. Borrowing availability under the credit
facility was reduced by $10 million until such quarter in 2003 in which the
trailing 12 month EBITDA, excluding certain restructuring costs and special
charges recorded by the Company during
- 24 -
fiscal 2002, as defined, exceeded $15 million. As of March 30, 2003, the
trailing 12 months EBITDA threshold was achieved and the availability
restriction lifted, effective June 1, 2003.
At the Company's option, the interest rate on borrowings under the
credit facility was based on the London Interbank Offered Rates (LIBOR) plus
3.25 percent or the lender's prime rate plus 1.25 percent. In addition, the
Company was required to pay a fee equal to 2.5 percent per annum of the
aggregate face amount of outstanding letters of credit. Beginning in 2003, the
applicable margin for the LIBOR borrowing, prime rate borrowing and letter of
credit fees decreases by 0.25 percent to 3.0 percent, 1.0 percent, and 2.25
percent, respectively, provided that the Company's trailing 12 month EBITDA,
excluding certain restructuring costs and special charges, as defined, is in
excess of $20 million. The Company was also subject to an unused line fee equal
to 0.50 percent per annum of the average daily difference between the total
revolving credit facility amount, as defined, and the total outstanding
borrowings and letters of credit. Beginning in 2003, the unused credit line fee
decreases to 0.375 percent provided the minimum EBITDA target described above is
achieved. The higher margins and fees are subject to reinstatement in the event
that the Company's trailing 12 month EBITDA falls below $20 million. The Company
met this minimum EBITDA requirement as of March 30, 2003, with the rate
reduction effective June 1, 2003 and continued to meet this requirement as of
December 28, 2003.
Total outstanding letters of credit were $20.8 million as of December
28, 2003. The letters of credit, which expire one year from date of issuance,
were issued to guarantee payments under the Company's workers compensation
program and for certain other commitments. As of December 28, 2003, there were
no borrowings outstanding under the credit facility and the Company had
borrowing capacity under the credit facility, after adjusting for outstanding
letters of credit, of approximately $34 million.
The credit facility, which expires in June 2006, includes certain
covenants requiring the Company to maintain a minimum tangible net worth of
$101.6 million, minimum EBITDA, as defined, and a minimum fixed charge coverage
ratio, as defined. Other covenants in the credit facility include limitation on
mergers, consolidations, acquisitions, indebtedness, liens, distributions
including dividends, capital expenditures, stock repurchases and dispositions of
assets and other limitations with respect to the Company's operations. On August
7, 2003, the credit facility was amended to make covenants relating to
acquisitions and stock repurchases less restrictive, provided that the Company
maintains minimum excess aggregate liquidity, as defined in the amendment, equal
to at least $60 million, and to allow for the disposition of certain assets.
The credit facility further provides that if the agreement is
terminated for any reason, the Company must pay an early termination fee equal
to $275,000 if the facility is terminated during the period from June 13, 2003
to June 12, 2004 and $137,500 if the facility is terminated from June 13, 2004
to June 12, 2005. There is no fee for termination of the facility subsequent to
June 12, 2005. Loans under the credit facility are collateralized by all of the
Company's tangible and intangible personal property, other than equipment.
The credit facility includes provisions, which, if not complied with,
could require early payment by the Company. These include customary default
events, such as failure to comply with financial covenants, insolvency events,
non-payment of scheduled payments, acceleration of other financial obligations
and change in control provisions. In addition, these provisions include an
account obligor, whose accounts are more than 25 percent of all accounts of the
Company over the previous 12-month period, canceling or failing to renew its
contract with the Company and ceasing to recognize the Company as an approved
provider of health care services, or the Company revoking the lending agent's
control over its governmental lockbox accounts. The Company does not have any
trigger events in the credit facility that are tied to changes in its credit
rating or stock price. As of December 28, 2003, the Company was in compliance
with these covenants.
The Company may be subject to workers compensation claims and lawsuits
alleging negligence or other similar legal claims. The Company maintains various
insurance programs to cover this risk but is substantially self-insured for most
of these claims. The Company recognizes its obligations associated with these
programs in the period the claim is incurred. The Company estimates the cost of
both reported claims and claims incurred but not reported, up to specified
deductible limits, based on its own specific historical claims experience and
current enrollment statistics, industry statistics and other information. Such
estimates and the resulting reserves are reviewed and updated periodically.
The Company is responsible for the cost of individual workers
compensation claims and individual professional liability claims up to $500,000
per incident which occurred prior to March 15, 2002 and $1,000,000 per incident
thereafter. The Company also maintains excess liability coverage relating to
professional liability and casualty claims which provides insurance coverage for
individual claims of up to $25,000,000 in excess of
- 25 -
the underlying coverage limits. Payments under the Company's workers
compensation program are guaranteed by letters of credit and segregated
restricted cash balances.
Additional items that could impact the Company's liquidity are
discussed under "Risk Factors" in Item 1 of this annual report on Form 10-K.
CAPITAL EXPENDITURES
The Company's capital expenditures from continuing operations for the
fiscal years 2003, 2002 and 2001 were $8.8 million, $4.1 million and $3.9
million, respectively. The Company intends to make investments and other
expenditures to, among other things, upgrade its computer technology and system
infrastructure. In this regard, management expects that capital expenditures
will range between $12 million and $13.5 million for fiscal 2004. Management
expects that the Company's capital expenditure needs will be met through
operating cash flow and available cash reserves.
CASH RESOURCES AND OBLIGATIONS
The Company had cash, cash equivalents, restricted cash and short-term
investments of approximately $110.0 million as of December 28, 2003. The
restricted cash relates to cash funds of $21.8 million that have been segregated
in a trust account to provide additional collateral and to replace approximately
$7 million of letters of credit and a $5 million surety bond which had been used
as collateral under the Company's insurance programs. Interest on the funds in
the trust account accrues to the Company. The Company, at its option, may access
the cash funds in the trust account by providing equivalent amounts of
alternative security, including letters of credit and surety bonds.
The Company anticipates that repayments to Medicare for partial
episode payments and prior year cost report settlements will be made
periodically through June 2005. These amounts are reflected as Medicare
liabilities in the accompanying consolidated balance sheets.
On May 16, 2003, the Company announced that its Board of Directors had
authorized the Company to repurchase and to formally retire up to 1,000,000
shares of its outstanding common stock. The repurchases were to occur
periodically in the open market or through privately negotiated transactions
based on market conditions and other factors. As of July 23, 2003, the Company
had repurchased all 1,000,000 shares of its common stock at an average cost of
$9.08 per share and at a total cost of approximately $9.1 million. On August 7,
2003, the Company's Board of Directors authorized the Company to repurchase and
formally retire up to an additional 1,500,000 shares of its outstanding common
stock. The repurchases will occur periodically in the open market or through
privately negotiated transactions based on market conditions and other factors.
As of December 28, 2003, the Company had repurchased 438,464 shares at an
average cost of $12.18 per share and a total cost of approximately $5.3 million.
For the period from December 29, 2003 through February 26, 2004, the Company
purchased 199,147 shares at an average cost of $12.77 per share and a total cost
of approximately $2.5 million.
CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENTS
At December 28, 2003, the Company had no long-term debt and no
significant capital lease obligations. Future minimum rental commitments for all
non-cancelable leases and purchase obligations at December 28, 2003, are as
follows (in thousands):
PAYMENT DUE BY PERIOD
---------------------------------------------------------
LESS THAN MORE THAN
CONTRACTUAL OBLIGATIONS TOTAL 1 YEAR 1-3 YEARS 4-5 YEARS 5 YEARS
----------------------- -------- --------- --------- --------- ---------
Long-term debt obligations $ - $ - $ - $ - $ -
Capital lease obligations - - - - -
Operating lease obligations 55,135 18,936 24,725 8,652 2,822
Purchase obligations 1,076 1,076 - - -
-------- -------- --------- --------- --------
Total $ 56,211 $ 20,012 $ 24,725 $ 8,652 $ 2,822
======== ======== ========= ========= ========
The Company had total letters of credit outstanding under its credit
facility of approximately $27.6 million at December 29, 2002 and $20.8 million
at December 28, 2003. The letters of credit, which expire one year
- 26 -
from date of issuance, are issued to guarantee payments under the Company's
workers compensation program and for certain other commitments. The Company has
the option to renew these letters of credit or set aside cash funds in a
segregated account to satisfy the Company's obligations as further discussed in
the "Liquidity and Capital Resources" section under the section "Cash Resources
and Obligations".
The Company has no other off-balance sheet arrangements and has not
entered into any transactions involving unconsolidated, limited purpose entities
or commodity contracts.
Management expects that the Company's working capital needs for fiscal
2004 will be met through operating cash flow and its existing cash balances. The
Company may also consider other alternative uses of cash including, among other
things, acquisitions, additional share repurchases and cash dividends. These
uses of cash would require the approval of the Company's Board of Directors and
may require the approval of its lender. If cash flows from operations, cash
resources or availability under the credit facility fall below expectations, the
Company may be forced to delay planned capital expenditures, reduce operating
expenses, seek additional financing or consider alternatives designed to enhance
liquidity.
LITIGATION AND GOVERNMENT MATTERS
The Company is a party to certain legal actions and government
investigations. See Item 3. "Legal Proceedings" and Note 9 to the Company's
consolidated financial statements.
SETTLEMENT ISSUES
PRRB APPEAL
As further described in the Critical Accounting Policies below, the
Company's annual cost reports, which were filed with the CMS, were subject to
audit by the fiscal intermediary engaged by CMS. In connection with the audit of
the Company's 1997 cost reports, the Medicare fiscal intermediary made certain
audit adjustments related to the methodology used by the Company to allocate a
portion of its residual overhead costs. The Company filed cost reports for years
subsequent to 1997 using the fiscal intermediary's methodology. The Company
believed its methodology used to allocate such overhead costs was accurate and
consistent with past practice accepted by the fiscal intermediary; as such, the
Company filed appeals with the Provider Reimbursement Review Board ("PRRB")
concerning this issue with respect to cost reports for the years 1997, 1998 and
1999. The Company's consolidated financial statements for the years 1997, 1998
and 1999 had reflected use of the methodology mandated by the fiscal
intermediary.
In June 2003, the Company and its Medicare fiscal intermediary signed
an Administrative Resolution relating to the issues covered by the appeals
pending before the PRRB. Under the terms of the Administrative Resolution, the
fiscal intermediary agreed to reopen and adjust the Company's cost reports for
the years 1997, 1998 and 1999 using a modified version of the methodology used
by the Company prior to 1997. This modified methodology will also be applied to
cost reports for the year 2000, which are currently under audit. The
Administrative Resolution required that the process to (i) reopen all 1997 cost
reports, (ii) determine the adjustments to allowable costs through the issuance
of Notices of Program Reimbursement ("NPRs") and (iii) make appropriate payments
to the Company, be completed in early 2004. Cost reports relating to years
subsequent to 1997 will be reopened after the process for the 1997 cost reports
is completed.
On February 17, 2004, the fiscal intermediary notified the Company
that it had completed the reopening of all 1997 cost reports and determined that
the adjustment to allowable costs for that year approximated $9 million. As of
February 27, 2004, the majority of the funds relating to this adjustment had
been remitted to the Company; the settlement amount will be recorded as net
revenues during the first quarter of fiscal 2004.
Although the Company believes that it could recover additional funds
as a result of applying the modified methodology discussed above to cost reports
subsequent to 1997, the settlement amounts cannot be specifically determined
until the reopening or audit of each year's cost reports is completed. This is
not expected to occur until the second half of fiscal 2004 or fiscal 2005.
However, in view of changes in reimbursement and the Company's operations in
periods subsequent to 1997, it is likely that future recoveries relating to any
cost report year from 1998 to 2000 will be significantly less than the 1997
settlement.
- 27 -
STOCK-BASED COMPENSATION
Statement of Financial Accounting Standards ("SFAS") No. 123,
"Accounting for Stock-Based Compensation" ("SFAS 123"), as amended by SFAS No.
148, "Accounting for Stock-Based Compensation - Transition and Disclosure and
amendment of Financial Accounting Standards Board ("FASB") Statement No. 123"
("SFAS 148") encourages, but does not require, companies to record compensation
cost for stock-based compensation plans at fair value. In addition, SFAS 148
provides alternative methods of transition for a voluntary change to the fair
value based method of accounting for stock-based employee compensation, and
amends the disclosure requirements of SFAS 123 to require prominent disclosures
in both annual and interim financial statements about the method of accounting
for stock-based employee compensation and the effect of the method used on
reported results.
The Company has chosen to adopt the disclosure only provisions of SFAS
148 and continue to account for stock-based compensation using the intrinsic
value method prescribed in Accounting Principles Board ("APB") Opinion No. 25,
"Accounting for Stock Issued to Employees" ("APB 25"), and related
interpretations. Under this approach, the cost of restricted stock awards is
expensed over their vesting period, while the imputed cost of stock option
grants and discounts offered under the Company's Employee Stock Purchase Plan
("ESPP") is disclosed, based on the vesting provisions of the individual grants,
but not charged to expense.
The Company has several stock ownership and compensation plans, which
are described more fully in Note 11 to the consolidated financial statements.
The following table presents net income (loss) and basic and diluted earnings
(loss) per common share, had the Company elected to recognize compensation cost
based on the fair value at the grant dates for stock option awards and discounts
granted for stock purchases under the Company's ESPP, consistent with the method
prescribed by SFAS 123, as amended by SFAS 148:
FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- ----------------- -----------------
Net income (loss) - as reported $ 56,766 $ (49,033) $ 20,988
Add: Stock-based employee compensation
expense included in reported net income, net of tax - 13,160 -
Deduct: Total stock-based compensation expense
determined under fair value based method for
all awards, net of tax (1,575) (5,022) (3,002)
-------- --------- --------
Net income (loss) - pro forma $ 55,191 $ (40,895) $ 17,986
======== ========= ========
Basic income (loss) per share - as reported $ 2.16 $ (1.87) $ 0.90
Basic income (loss) per share - pro forma $ 2.10 $ (1.56) $ 0.78
Diluted income (loss) per share - as reported $ 2.07 $ (1.87) $ 0.90
Diluted income (loss) per share - pro forma $ 2.01 $ (1.56) $ 0.78
GOODWILL AND OTHER INTANGIBLE ASSETS ("SFAS 142")
In June 2001, the FASB issued SFAS No. 142 "Goodwill and Other
Intangible Assets" ("SFAS 142"), which broadens the criteria for recording
intangible assets separate from goodwill. SFAS 142 requires the use of a
non-amortization approach to account for purchased goodwill and certain
intangibles. Under a non-amortization approach, goodwill and certain intangibles
are not amortized into results of operations, but instead are reviewed for
impairment and an impairment charge is recorded in the periods in which the
recorded carrying value of goodwill and certain intangibles is more than its
estimated fair value. The Company adopted SFAS 142 as of the beginning of fiscal
2002. The provisions of SFAS 142 require that a transitional impairment test be
performed as of the beginning of the year the statement is adopted.
Based on the results of the transitional impairment tests, the Company
determined that an impairment loss relating to goodwill had occurred and
recorded a non-cash charge of $187.1 million, net of a deferred tax benefit of
$30.2 million, as cumulative effect of accounting change in the accompanying
consolidated statement of operations for the fiscal year ended December 29,
2002. The deferred tax benefit was recorded by eliminating a deferred tax
liability of $26.8 million and recording a deferred tax asset of approximately
$39 million, offset by an increase in the tax valuation allowance by the same
amount. During fiscal 2002, the Company also recorded a tax benefit of
approximately $3.4 million relating to tax deductible goodwill. See Note 12 to
the consolidated financial statements.
- 28 -
For fiscal year 2001, intangibles, principally goodwill, associated
with acquired businesses were being amortized on a straight-line basis over
periods ranging from 10 to 40 years in accordance with APB Opinion No. 17,
"Intangible Assets" based on a fair value methodology.
The table below presents a reconciliation of reported net income to
adjusted net income as if SFAS 142 was adopted as of January 1, 2001 (in
thousands, except per share amounts).
FOR THE FISCAL YEAR ENDED
DECEMBER 30, 2001
-------------------------------
EARNINGS PER SHARE
NET INCOME BASIC AND DILUTED
---------- ------------------
Reported net income $ 20,988 $ 0.90
Add back: Goodwill amortization, net of tax 10,023 0.43
-------- -------
Adjusted net income $ 31,011 $ 1.33
======== =======
The provisions of SFAS 142 also require that a goodwill impairment
test be performed annually or on the occasion of other events that indicate a
potential impairment. The annual impairment test of goodwill was performed and
indicated that there was no impairment of goodwill as of December 28, 2003.
RECENT ACCOUNTING PRONOUNCEMENTS
In July 2002, the FASB issued SFAS No. 146 "Accounting for Costs
Associated with Exit or Disposal Activities" ("SFAS 146"), which addresses the
recognition, measurement, and reporting of costs associated with exit or
disposal activities, and supersedes Emerging Issues Task Force ("EITF") Issue
No. 94-3 "Liability Recognition for Certain Employee Termination Benefits and
Other Costs to Exit An Activity (including Certain Costs Incurred in a
Restructuring)" ("EITF 94-3"). The principal difference between SFAS 146 and
EITF 94-3 relates to the requirements for recognition of a liability for a cost
associated with an exit or disposal activity. SFAS 146 requires that a liability
for a cost associated with an exit or disposal activity, including those related
to employee termination benefits and obligations under operating leases and
other contracts, be recognized when the liability is incurred, and not
necessarily the date of an entity's commitment to an exit plan, as under EITF
94-3. SFAS 146 also establishes that the initial measurement of a liability
recognized under SFAS 146 be based on fair value. The provisions of SFAS 146 are
effective for exit or disposal activities that are initiated after December 31,
2002, with early application encouraged. The Company adopted SFAS 146, effective
December 30, 2002. For exit or disposal activities initiated prior to December
30, 2002, the Company followed the accounting guidelines outlined in EITF 94-3.
In January 2003, the FASB issued Interpretation No. 46, "Consolidation
of Variable Interest Entities," as revised in December 2003 ("FIN 46"). FIN 46
requires a variable interest entity to be consolidated by a company if that
company is subject to a majority of the risk of loss from the variable interest
entity's activities or entitled to receive a majority of the entity's residual
returns or both. Historically, entities generally were not consolidated unless
the entity was controlled through voting interests. FIN 46 also requires
disclosures about variable interest entities that a company is not required to
consolidate but in which it has a significant variable interest. The
consolidation requirements of FIN 46 will apply to variable interest entities as
of March 31, 2004 for the Company. Also, certain disclosure requirements apply
to all financial statements issued after December 31, 2003, regardless of when
the variable interest entity was established. The adoption of this standard is
not expected to have a material impact on the Company's consolidated financial
statements.
IMPACT OF INFLATION
The Company does not believe that inflation has had a material impact
on its results of operations during the past three fiscal years.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
estimates and assumptions and select accounting policies that affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date
- 29 -
of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
The most critical estimates relate to revenue recognition, the collectibility of
accounts receivable and related reserves, the cost of claims incurred but not
reported, obligations under workers compensation, professional liability and
employee health and welfare insurance programs and Medicare settlement issues. A
description of the critical accounting policies and a discussion of the
significant estimates and judgments associated with such policies are described
below.
REVENUE RECOGNITION
Under fee-for-service agreements with patients and commercial and
certain government payors, net revenues are recorded based on net realizable
amounts to be received in the period in which the services and products are
provided or delivered. Fee-for-service contracts with commercial payors are
traditionally one year in term and renewable automatically on an annual basis,
unless terminated by either party.
Under capitated arrangements with certain managed care customers, net
revenues are recognized based on a predetermined monthly contractual rate for
each member of the managed care plan regardless of the services provided. Net
revenues generated under capitated agreements were approximately 16 percent, 16
percent, and 15 percent of total net revenues for fiscal 2003, 2002, 2001,
respectively.
Under the Prospective Payment System ("PPS") for Medicare
reimbursement, net revenues are recorded based on a reimbursement rate which
varies based on the severity of the patient's condition, service needs and
certain other factors; revenue is recognized ratably over the period in which
services are provided. Revenue is subject to adjustment during this period if
there are significant changes in the patient's condition during the treatment
period or if the patient is discharged but readmitted to another agency within
the same 60 day episodic period. Medicare billings under PPS are initially
recognized as deferred revenue and are subsequently amortized into revenue over
an average patient treatment period. The process for recognizing revenue to be
recognized under the Medicare program is based on certain assumptions and
judgments, including the average length of time of each treatment as compared to
a standard 60 day episode, the appropriateness of the clinical assessment of
each patient at the time of certification and the level of adjustments to the
fixed reimbursement rate relating to patients who receive a limited number of
visits, have significant changes in condition or are subject to certain other
factors during the episode. Deferred revenue of approximately $5.2 million and
$4.4 million relating to the Medicare PPS program was included in other Medicare
liabilities in the consolidated balance sheets as of December 28, 2003 and
December 29, 2002, respectively.
Revenue adjustments result from differences between estimated and
actual reimbursement amounts, an inability to obtain appropriate billing
documentation or authorizations acceptable to the payor and other reasons
unrelated to credit risk. Revenue adjustments are deducted from gross accounts
receivable. These revenue adjustments are based on significant assumptions and
judgments which are determined by Company management based on historical trends.
Third party settlements resulting in recoveries are recognized as net revenues
in the period in which the funds are received.
COLLECTIBILITY OF ACCOUNTS RECEIVABLE
The process for estimating the ultimate collection of receivables,
particularly with respect to fee-for-service arrangements, involves significant
assumptions and judgments. In this regard, the Company has implemented a
standardized approach to estimate and review the collectibility of its
receivables based on accounts receivable aging trends. Historical collection and
payor reimbursement experience is an integral part of the estimation process
related to determining the allowance for doubtful accounts. In addition, the
Company assesses the current state of its billing functions in order to identify
any known collection or reimbursement issues to determine the impact, if any, on
its reserve estimates, which involve judgment. Revisions in reserve estimates
are recorded as an adjustment to the provision for doubtful accounts which is
reflected in selling, general and administrative expenses in the consolidated
statements of operations. The Company believes that its collection and reserve
processes, along with the monitoring of its billing processes, help to reduce
the risk associated with material revisions to reserve estimates resulting from
adverse changes in collection, reimbursement experience and billing functions.
- 30 -
COST OF CLAIMS INCURRED BUT NOT REPORTED
Under capitated arrangements with managed care customers, the Company
estimates the cost of claims incurred but not reported based on applying
actuarial assumptions, historical patterns of utilization to authorized levels
of service, current enrollment statistics and other information. Under
fee-for-service arrangements with certain managed care customers, the Company
also estimates the cost of claims incurred but not reported and the estimated
revenue relating thereto in situations in which the Company is responsible for
care management and patient services are performed by a non-affiliated provider.
The estimate of cost of claims incurred but not reported involves
significant assumptions and judgments which relate to and may vary depending on
the services authorized at each of the Company's regional coordination centers,
historical patterns of service utilization and payment trends. These assumptions
and judgments are evaluated on a quarterly basis and changes in estimated
liabilities for costs of claims incurred but not reported are determined based
on such evaluation.
OBLIGATIONS UNDER INSURANCE PROGRAMS
The Company is obligated for certain costs under various insurance
programs, including workers compensation and professional liability and employee
health and welfare.
The Company may be subject to workers compensation claims and lawsuits
alleging negligence or other similar legal claims. The Company maintains various
insurance programs to cover this risk but is substantially self-insured for most
of these claims. The Company recognizes its obligations associated with these
programs in the period the claim is incurred. The cost of both reported claims
and claims incurred but not reported, up to specified deductible limits, have
generally been estimated based on historical data, industry statistics, the
Company's own home health specific historical claims experience, current
enrollment statistics and other information. Such estimates and the resulting
reserves are reviewed and updated periodically.
For the fiscal year ended December 29, 2002, the Company recorded a
special charge of $6.3 million relating primarily to a refinement in the
estimation process used to determine the Company's actuarially computed workers
compensation and professional liability reserves. Management believes that, as a
result of this refinement, sufficient data exists to allow the Company to more
heavily rely on its own home health specific historical claims experience in
determining the Company's estimates of workers compensation and professional
liability reserves. Previously the Company utilized insurance industry actuarial
information, as well as the Company's historical claims experience in developing
reserve estimates.
The Company maintains insurance coverage on individual claims. The
Company is responsible for the cost of individual workers compensation claims
and individual professional liability claims up to $500,000 per incident which
occurred prior to March 15, 2002 and $1,000,000 per incident thereafter. The
Company also maintains excess liability coverage relating to professional
liability and casualty claims which provides insurance coverage for individual
claims of up to $25,000,000 in excess of the underlying coverage limits.
Payments under the Company's workers compensation program are guaranteed by
letters of credit and segregated restricted cash balances. During the fiscal
year 2003, the Company segregated $21.8 million of cash funds in a trust account
to replace certain letters of credit and surety bonds. Interest on the funds in
the trust account accrues to the Company.
The Company, at its option, may terminate the trust agreement by
providing equivalent amounts of alternative security allowed under the program,
including letters of credit and surety bonds. The Company believes that its
present insurance coverage and reserves are sufficient to cover currently
estimated exposures, but there can be no assurance that the Company will not
incur liabilities in excess of recorded reserves or in excess of its insurance
limits.
MEDICARE SETTLEMENT ISSUES
- 31 -
Prior to October 1, 2000, reimbursement of Medicare home care nursing
services was based on reasonable, allowable costs incurred in providing services
to eligible beneficiaries subject to both per visit and per beneficiary limits
in accordance with the Interim Payment System established through the Balanced
Budget Act of 1997. These costs were reported in annual cost reports which were
filed with the Centers for Medicare and Medicaid Services ("CMS") and were
subject to audit by the fiscal intermediary engaged by CMS. The fiscal
intermediary has not finalized its audit of the fiscal 2000 cost reports.
Furthermore, settled cost reports relating to certain years prior to fiscal 2000
could be subject to reopening of the audit process by the fiscal intermediary.
Although management believes that established reserves are sufficient, it is
possible that adjustments resulting from such audits could result in adjustments
to the consolidated financial statements that exceed established reserves.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company had no interest rate exposure on fixed rate debt or other
market risk at December 28, 2003.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements and financial statement schedule
set forth in Part IV, Item 15 (a) (1) and (2) of this report are incorporated by
reference into this Item 8.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
There have been no such changes or disagreements.
ITEM 9A. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES.
The Company's Chief Executive Officer and Chief Financial Officer have
evaluated the effectiveness of the design and operation of the Company's
disclosure controls and procedures (as defined in the Securities Exchange Act of
1934 ("Exchange Act") Rule 13a-15(e)) as of the end of the period covered by
this report. Based on that evaluation, the Company's Chief Executive Officer and
Chief Financial Officer have concluded that the Company's disclosure controls
and procedures are adequate and effective to ensure that information required to
be disclosed by the Company in reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported within required
time periods.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING.
As required by the Exchange Act Rule 13a-15(d), the Company's Chief
Executive Officer and Chief Financial Officer evaluated the Company's internal
control over financial reporting to determine whether any change occurred during
the quarter ended December 28, 2003 that has materially affected, or is
reasonably likely to materially affect, the Company's internal control over
financial reporting. Based on that evaluation, there has been no such change
during such quarter.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Information required by this item regarding the directors of the
Company is incorporated herein by reference to information under the captions
"Proposal 1 Election of Directors" and "Board of Directors and Committees" to be
contained in the Company's Proxy Statement to be filed with the SEC with regard
to the Company's 2004 Annual Meeting of Shareholders ("2004 Proxy Statement").
See also the information regarding executive officers of the Company at the end
of PART I hereof.
Certain other information required by this item is incorporated herein
by reference to information under the caption "Section 16(a) Beneficial
Ownership Reporting Compliance" to be contained in the Company's 2004 Proxy
Statement.
- 32 -
The Company has adopted a Code of Ethics for Senior Financial Officers
("Code of Ethics") that applies to the Company's Chief Executive Officer, Chief
Financial Officer and Principal Accounting Officer or Controller. A copy of the
Code of Ethics is posted on its Internet website www.gentiva.com under the
"Investor Relations" section. In the event that the Company makes any amendment
to, or grants any waiver from, a provision of the Code of Ethics that requires
disclosure under applicable SEC rules, the Company intends to disclose such
amendment or waiver on its website.
ITEM 11. EXECUTIVE COMPENSATION
Information required by this item concerning executive compensation
and compensation of directors is incorporated herein by reference to information
under the captions "Executive Compensation" and "Board of Directors and
Committees," respectively, to be contained in the Company's 2004 Proxy
Statement.
ITEM 12. SECURITIES OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
Information required by this item regarding the security ownership of
certain beneficial owners and management of the Company is incorporated herein
by reference to information under the caption "Security Ownership of Certain
Beneficial Owners and Management" to be contained in the Company's 2004 Proxy
Statement.
Certain other information required by this item regarding securities
authorized for issuance under the Company's equity compensation plans is
incorporated herein by reference to information under the caption "Equity
Compensation Plan Information" to be contained in the Company's 2004 Proxy
Statement.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
There are no such relationships or transactions.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Information regarding principal accountant fees and services is
incorporated herein by reference to information under the caption "Proposal 2
Appointment of Independent Public Accountants" to be contained in the Company's
2004 Proxy Statement.
- 33 -
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a)(1) FINANCIAL STATEMENTS
PAGE NO.
--------
o Report of Independent Auditors................................................................. F-2
o Consolidated Balance Sheets as of December 28, 2003 and December 29, 2002...................... F-3
o Consolidated Statements of Operations for the three years ended December 28, 2003.............. F-4
o Consolidated Statements of Changes in Shareholders' Equity for the three years ended
December 28, 2003.............................................................................. F-5
o Consolidated Statements of Cash Flows for the three years ended December 28, 2003.............. F-6
o Notes to Consolidated Financial Statements..................................................... F-7
(a)(2) FINANCIAL STATEMENT SCHEDULE
o Schedule II - Valuation and Qualifying Accounts for the three years ended December 28, 2003.... F-27
(a)(3) EXHIBITS
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
3.1 Restated Certificate of Incorporation of Company(1)
3.2 Certificate of Correction to Certificate of Incorporation, filed with
the Delaware Secretary of State on July 1, 2002(2)
3.3 Restated By-Laws of Company(2)
4.1 Specimen of common stock(4)
4.2 Form of Certificate of Designation of Series A Junior Participating
Preferred Stock(1)
4.3 Form of Certificate of Designation of Series A Cumulative Non-Voting
Redeemable Preferred Stock(3)
10.1 Separation Agreement dated August 17, 1999 among Olsten Corporation,
Aaronco Corp. and Adecco SA(1)
10.2 Omnibus Amendment No. 1 dated October 7, 1999 by and among Olsten
Corporation, Aaronco Corp., Adecco SA and Olsten Health Services
Holding Corp.(1)
- 34 -
10.3 Omnibus Amendment No. 2 dated January 18, 2000 by and among Olsten
Corporation, Adecco SA, Olsten Health Services Holding Corp., the
Company and Staffing Acquisition Corporation (1)
10.4 Form of Rights Agreement dated March 2, 2000 between the Company and
EquiServe Trust Company, N.A., as rights agent(3)
10.5 Company's Executive Officers Bonus Plan(1)*
10.6 Company's 1999 Stock Incentive Plan(5)*
10.7 Company's Stock & Deferred Compensation Plan for Non-Employee
Directors, as amended and restated as of April 1, 2000 (5)*
10.8 Company's Stock & Deferred Compensation Plan for Non-Employee
Directors, as amended and restated as of January 1, 2004+*
10.9 Company's Employee Stock Purchase Plan (1)*
10.10 Company's Nonqualified Retirement and Savings Plan and First, Second,
Third and Fourth Amendments thereto+*
10.11 Form of Change in Control Agreement with Executive Officers of
Company(2) *
10.12 Form of Severance Agreement with Executive Officers of Company (2)*
10.13 Employment Agreement with Ronald A. Malone (6)*
10.14 Change in Control Agreement with Ronald A. Malone (2)*
10.15 Loan and Security Agreement dated June 13, 2002 by and between Fleet
Capital Corporation, as Administrative Agent, on behalf of the lenders
named therein, Fleet Securities, Inc., as Arranger, Gentiva Health
Services, Inc., Gentiva Health Services Holding Corp. and the
subsidiaries named therein (7)
10.16 First Amendment and Consent Agreement dated August 7, 2003 to Loan and
Security Agreement dated June 13, 2002 by and between Fleet Capital
Corporation, as Administrative Agent on behalf of the lenders named
therein, Fleet Securities, Inc., as Arranger, Gentiva Health Services,
Inc., Gentiva Health Services Holding Corp. and the subsidiaries named
therein (8)
10.17 Second Amendment dated November 26, 2003 to Loan and Security
Agreement dated June 13, 2002 by and between Fleet Capital
Corporation, as Administrative Agent on behalf of the lenders named
therein, Fleet Securities, Inc., as Arranger, Gentiva Health Services,
Inc., Gentiva Health Services Holding Corp. and the subsidiaries named
therein+
10.18 Third Amendment and Joinder dated February 25, 2004 to Loan and
Security Agreement dated June 13, 2002 by and between Fleet Capital
Corporation, as Administrative Agent on behalf of the lenders named
therein, Fleet Securities, Inc., as Arranger, Gentiva Health
Services., Inc., Gentiva Health Services Holding Corp. and the
subsidiaries named therein.+
10.19 Asset Purchase Agreement dated as of January 2, 2002 by and between
Accredo Health, Incorporated, the Company and the Sellers named
therein (9)
- 35 -
10.20 National Home Care Provider Agreement between CIGNA Health Corporation
and Gentiva CareCentrix, Inc. dated January 1, 1996, as amended (10)
(confidential treatment requested as to portions of this document)
10.21 Amendment dated January 1, 2003 to National Home Care Provider
Agreement between CIGNA Health Corporation and Gentiva CareCentrix,
Inc. dated January 1, 1996, as amended (6) (confidential treatment
requested as to portions of this document)
10.22 Managed Care Alliance Agreement between CIGNA Health Corporation and
Gentiva CareCentrix, Inc. entered into as of January 1, 2004
+(confidential treatment requested as to portions of this document)
10.23 Consulting Agreement dated as of July 1, 2002 between Gail R. Wilensky
and Gentiva Health Services (USA), Inc. (11)*
10.24 Amendment dated August 7, 2003 to Consulting Agreement dated as of
July 1, 2002 between Gail R. Wilensky and Gentiva Health Services
(USA), Inc. (8)*
21. List of Subsidiaries of Company +
23. Consent of PricewaterhouseCoopers LLP, independent accountants +
31.1 Certification of Chief Executive Officer dated March 1, 2004 pursuant
to Rule 13a-14(a)+
31.2 Certification of Chief Financial Officer dated March 1, 2004 pursuant
to Rule 13a-14(a)+
32.1 Certification of Chief Executive Officer dated March 1, 2004 pursuant
to 18 U.S.C. Section 1350+
32.2 Certification of Chief Financial Officer dated March 1, 2004 pursuant
to 18 U.S.C. Section 1350+
- ----------
(1) Incorporated herein by reference to Amendment No. 2 to the
Registration Statement of Company on Form S-4 dated January 19, 2000
(File No. 333-88663).
(2) Incorporated herein by reference to Form 10-Q of Company for quarterly
period ended June 30, 2002.
(3) Incorporated herein by reference to Amendment No. 3 to the
Registration Statement of Company on Form S-4 dated February 4, 2000
(File No. 333-88663).
(4) Incorporated herein by reference to Amendment No. 4 to the
Registration Statement of Company on Form S-4 dated February 9, 2000
(File No. 333-88663).
(5) Incorporated herein by reference to Form 10-K of Company for the
fiscal year ended January 2, 2000.
(6) Incorporated herein by reference to Form 10-K of Company for the
fiscal year ended December 29, 2002.
(7) Incorporated herein by reference to Form 8-K of Company dated June 13,
2002 and filed June 21, 2002.
(8) Incorporated herein by reference to Form 10-Q of Company for quarterly
period ended September 28, 2003.
(9) Incorporated herein by reference to definitive Proxy Statement of
Company dated May 10, 2002.
(10) Incorporated herein by reference to Form 10-Q of Company for quarterly
period ended September 29, 2002.
- 36 -
(11) Incorporated herein by reference to Form 10-Q of Company for quarterly
period ended March 30, 2003.
* Management contract or compensatory plan or arrangement
+ Filed herewith
(b) REPORTS ON FORM 8-K
On October 30, 2003, the Company furnished a report on Form 8-K (i)
furnishing in Item 7 as an exhibit a press release covering the Company's 2003
third quarter consolidated earnings and (ii) reporting in Item 12 the issuance
of the Company's press release on the subject of its 2003 third quarter
consolidated earnings.
- 37 -
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
GENTIVA HEALTH SERVICES, INC.
Date: March 1, 2004 By: /s/ RONALD A. MALONE
--------------------
Ronald A. Malone
Chief Executive Officer and Chairman of the
Board
Pursuant to the requirements of Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Date: March 1, 2004 By: /s/ RONALD A. MALONE
--------------------
Ronald A. Malone
Chief Executive Officer and Chairman of the
Board and Director (Principal Executive
Officer)
Date: March 1, 2004 By: /s/ JOHN R. POTAPCHUK
---------------------
John R. Potapchuk
Senior Vice President, Chief Financial
Officer, Treasurer and Secretary (Principal
Financial and Accounting Officer)
Date: March 1, 2004 By: /s/ EDWARD A. BLECHSCHMIDT
--------------------------
Edward A. Blechschmidt
Director
Date: March 1, 2004 By: /s/ VICTOR F. GANZI
-------------------
Victor F. Ganzi
Director
Date: March 1, 2004 By: /s/ STUART R. LEVINE
--------------------
Stuart R. Levine
Director
Date: March 1, 2004 By: /s/ MARY O'NEIL MUNDINGER
-------------------------
Mary O'Neil Mundinger
Director
Date: March 1, 2004 By: /s/ STUART OLSTEN
-----------------
Stuart Olsten
Director
Date: March 1, 2004 By: /s/ RAYMOND S. TROUBH
---------------------
Raymond S. Troubh
Director
Date: March 1, 2004 By: /s/ JOSH S. WESTON
------------------
Josh S. Weston
Director
Date: March 1, 2004 By: /s/ GAIL R. WILENSKY
--------------------
Gail R. Wilensky
Director
- 38 -
GENTIVA HEALTH SERVICES, INC. AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
PAGE NO.
--------
Report of Independent Auditors....................................................................... F-2
Consolidated Balance Sheets as of December 28, 2003 and December 29, 2002............................ F-3
Consolidated Statements of Operations for the three years ended December 28, 2003.................... F-4
Consolidated Statements of Changes in Shareholders' Equity for the three years ended
December 28, 2003................................................................................. F-5
Consolidated Statements of Cash Flows for the three years ended December 28, 2003.................... F-6
Notes to Consolidated Financial Statements........................................................... F-7
Schedule II - Valuation and Qualifying Accounts for the three years ended December 28, 2003.......... F-27
F-1
REPORT OF INDEPENDENT AUDITORS
To the Board of Directors and Shareholders of
Gentiva Health Services, Inc. and Subsidiaries:
In our opinion, the consolidated financial statements listed in the index
appearing under Item 15 (a)(1) present fairly, in all material respects, the
financial position of Gentiva Health Services, Inc. and Subsidiaries (the
"Company") at December 28, 2003 and December 29, 2002, and the results of their
operations and their cash flows for each of the three years in the period ended
December 28, 2003 in conformity with accounting principles generally accepted in
the United States of America. In addition, in our opinion, the financial
statement schedule listed in the index appearing under Item 15(a)(2) presents
fairly, in all material respects, the information set forth therein when read in
conjunction with the related consolidated financial statements. These financial
statements and financial statement schedule are the responsibility of the
Company's management; our responsibility is to express an opinion on these
financial statements and financial statement schedule based on our audits. We
conducted our audits of these statements in accordance with auditing standards
generally accepted in the United States of America, which require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
As discussed in Note 2 to the consolidated financial statements, the Company
adopted SFAS No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"), which
changed the method of accounting for goodwill and other intangible assets
effective December 31, 2001.
/s/ PRICEWATERHOUSECOOPERS LLP
- ------------------------------
PricewaterhouseCoopers LLP
Stamford, Connecticut
February 6, 2004, except for Note 9, as to which the date is February 27, 2004
F-2
GENTIVA HEALTH SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE AMOUNTS)
DECEMBER 28, 2003 DECEMBER 29, 2002
----------------- -----------------
ASSETS
Current assets:
Cash and cash equivalents $ 78,263 $ 101,241
Restricted cash 21,750 -
Short-term investments 10,000 -
Receivables, less allowance for doubtful accounts of
$7,936 and $9,032 in 2003 and 2002, respectively 132,998 125,078
Deferred tax assets 26,464 752
Prepaid expenses and other current assets 6,524 9,782
--------- ---------
Total current assets 275,999 236,853
Fixed assets, net 15,135 13,025
Deferred tax assets, net 28,025 -
Other assets 15,929 14,553
--------- ---------
Total assets $ 335,088 $ 264,431
========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 16,079 $ 16,865
Payroll and related taxes 12,932 12,377
Medicare liabilities 12,736 11,880
Cost of claims incurred but not reported 28,525 27,899
Obligations under insurance programs 37,200 37,829
Other accrued expenses 32,230 25,664
--------- ---------
Total current liabilities 139,702 132,514
Other liabilities 18,207 18,869
Shareholders' equity:
Common stock, $.10 par value; authorized 100,000,000
shares; issued and outstanding 25,598,301 and
26,385,210 shares, in 2003 and 2002, respectively 2,560 2,639
Additional paid-in capital 270,468 263,024
Accumulated deficit (95,849) (152,615)
--------- ---------
Total shareholders' equity 177,179 113,048
--------- ---------
Total liabilities and shareholders' equity $ 335,088 $ 264,431
========= =========
See notes to consolidated financial statements.
F-3
GENTIVA HEALTH SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
FOR THE FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- ----------------- -----------------
Net revenues $ 814,029 $ 768,501 $ 729,577
Cost of services sold 531,987 520,901 483,917
---------- ---------- ----------
Gross profit 282,042 247,600 245,660
Selling, general and administrative expenses (252,334) (276,355) (247,581)
Depreciation and amortization (6,851) (7,185) (18,741)
---------- ---------- ----------
Operating income (loss) 22,857 (35,940) (20,662)
Interest income (expense), net 441 834 (63)
---------- ---------- ----------
Income (loss) before income taxes from continuing
operations 23,298 (35,106) (20,725)
Income tax benefit (expense) 33,468 (18,437) 6,815
---------- ---------- ----------
Income (loss) from continuing operations 56,766 (53,543) (13,910)
Discontinued operations, net of tax - 191,578 34,898
---------- ---------- ----------
Income before cumulative effect of accounting change 56,766 138,035 20,988
Cumulative effect of accounting change, net of tax - (187,068) -
---------- ---------- ----------
Net income (loss) $ 56,766 $ (49,033) $ 20,988
========== ========== ==========
Basic earnings per share:
Income (loss) from continuing operations $ 2.16 $ (2.05) $ (0.60)
Discontinued operations, net of tax - 7.32 1.50
Cumulative effect of accounting change, net of tax - (7.14) -
---------- ---------- ----------
Net income (loss) $ 2.16 $ (1.87) $ 0.90
========== ========== ==========
Weighted average shares outstanding 26,262 26,183 23,186
========== ========== ==========
Diluted earnings per share:
Income (loss) from continuing operations $ 2.07 $ (2.05) $ (0.60)
Discontinued operations, net of tax - 7.32 1.50
Cumulative effect of accounting change, net of tax - (7.14) -
---------- ---------- ----------
Net income (loss) $ 2.07 $ (1.87) $ 0.90
========== ========== ==========
Weighted average shares outstanding 27,439 26,183 23,186
========== ========== ==========
See notes to consolidated financial statements.
F-4
GENTIVA HEALTH SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
CHANGES IN SHAREHOLDERS' EQUITY
FOR THE THREE YEARS ENDED DECEMBER 28, 2003
(IN THOUSANDS, EXCEPT SHARE AMOUNTS)
ACCUMULATED
COMMON STOCK ADDITIONAL OTHER
-------------------------- PAID-IN ACCUMULATED COMPREHENSIVE
SHARES AMOUNT CAPITAL DEFICIT INCOME (LOSS) TOTAL
------------ ------------ ------------ ------------ ------------- -----------
Balance at December 31, 2000 21,196,693 $ 2,120 $ 689,163 $ (124,570) $ (564) $ 566,149
Comprehensive income:
Net income 20,988 - 20,988
Realized gain on investments - 564 564
------------ ------------ ------------ ------------ --------- -----------
Subtotal - - - 20,988 564 21,552
Conversion of Gentiva-obligated man-
datorily redeemable convertible
securities of a subsidiary holding
solely Gentiva debentures 2,146,105 214 19,786 - - 20,000
Issuance of stock upon exercise of
stock options and under stock plans
for employees and directors 2,295,996 230 13,776 - - 14,006
------------ ------------ ------------ ------------ --------- -----------
Balance at December 30, 2001 25,638,794 $ 2,564 $ 722,725 $ (103,582) $ - $ 621,707
Comprehensive loss:
Net loss - - - (49,033) - (49,033)
Dividends paid ($17.75 per share) - - (466,597) - - (466,597)
Issuance of stock upon exercise of
stock options and under stock plans
for employees and directors 746,416 75 6,896 - - 6,971
------------ ------------ ------------ ------------ --------- -----------
Balance at December 29, 2002 26,385,210 $ 2,639 $ 263,024 $ (152,615) $ - $ 113,048
Comprehensive income:
Net income 56,766 56,766
Income tax benefits associated with
stock-based compensation 19,454 - 19,454
Issuance of stock upon exercise of
stock options and under stock plans
for employees and directors 651,555 65 2,271 - 2,336
Repurchase of common stock at cost (1,438,464) (144) (14,281) - (14,425)
------------ ------------ ------------ ------------ --------- -----------
Balance at December 28, 2003 25,598,301 $ 2,560 $ 270,468 $ (95,849) $ - $ 177,179
============ ============ ============ ============ ========= ===========
See notes to consolidated financial statements
F-5
GENTIVA HEALTH SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
FOR THE FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- ----------------- -----------------
OPERATING ACTIVITIES:
Net income (loss) $ 56,766 $ (49,033) $ 20,988
Adjustments to reconcile net income (loss) to net cash
provided by operating activities
Income from discontinued operations - (191,578) (34,898)
Cumulative effect of accounting change - 187,068 -
Depreciation and amortization 6,851 7,185 18,741
Provision for doubtful accounts 7,684 4,936 5,120
(Gain) loss on sale / disposal of businesses and
fixed assets (209) 951 (255)
Stock option tender offer - 21,388 -
Deferred income tax (benefit) expense (35,035) 12,837 -
Changes in assets and liabilities, net of
acquisitions/divestitures
Accounts receivable (15,604) 10,281 32,655
Prepaid expenses and other current assets 3,048 7,825 2,610
Current liabilities 7,065 6,393 (11,702)
Change in net assets held for sale - 3,300 57,711
Other, net 137 (3,024) 827
----------- ----------- -----------
Net cash provided by operating activities 30,703 18,529 91,797
----------- ----------- -----------
INVESTING ACTIVITIES:
Purchase of fixed assets - continuing operations (8,777) (4,116) (3,864)
Purchase of fixed assets - discontinued operations - (2,121) (6,203)
Proceeds from sale of assets / business 200 206,564 475
Acquisition of businesses (1,300) - -
Purchase of short-term investments (24,900) - -
Maturities of short-term investments 14,935 - -
Withdrawal from (deposits into) restricted cash (21,750) 35,164 (35,164)
----------- ----------- -----------
Net cash (used in) provided by investing activities (41,592) 235,491 (44,756)
----------- ----------- -----------
FINANCING ACTIVITIES:
Proceeds from issuance of common stock 2,336 6,971 14,006
Repurchases of common stock (14,425) - -
Debt issuance costs - (1,321) -
Cash distribution to shareholders - (203,983) -
Payments for stock option tender - (21,388) -
Advance (paid to) / received from Medicare program - (5,038) 20,878
Decrease in book overdrafts - - (10,379)
----------- ----------- -----------
Net cash (used in) provided by financing activities (12,089) (224,759) 24,505
----------- ----------- -----------
Net change in cash and cash equivalents (22,978) 29,261 71,546
Cash and cash equivalents at beginning of period 101,241 71,980 434
----------- ----------- -----------
Cash and cash equivalents at end of period $ 78,263 $ 101,241 $ 71,980
=========== =========== ===========
SUPPLEMENTAL SCHEDULE OF NON CASH INVESTING AND FINANCING ACTIVITIES
For fiscal year 2003, in connection with the reversal of the valuation
allowance, deferred tax benefits associated with stock compensation deductions
of $19.5 million have been credited to shareholders' equity.
For fiscal year 2002, in connection with the sale of the Company's Specialty
Pharmaceutical Services business on June 13, 2002, the Company received
5,060,976 shares of common stock of Accredo Health, Incorporated, which were
subsequently distributed to the Company's shareholders.
In fiscal 2001, $20 million of the Company's convertible preferred trust
securities were converted to common stock.
See notes to consolidated financial statements.
F-6
GENTIVA HEALTH SERVICES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. BACKGROUND AND BASIS OF PRESENTATION
Gentiva Health Services, Inc. ("Gentiva" or the "Company") provides
home health services throughout most of the United States. Gentiva was
incorporated in the state of Delaware on August 6, 1999 and became an
independent publicly owned company on March 15, 2000, when the common stock of
the Company was issued to the stockholders of Olsten Corporation ("Olsten"), the
former parent corporation of the Company (the "Split-Off"). Continuing
operations for all periods presented comprise the operating results of the home
health services business, including, for fiscal 2002 and 2001, restructuring and
other special charges as described in Note 4.
On June 13, 2002, the Company sold substantially all of the assets of
its specialty pharmaceutical services ("SPS") business to Accredo Health,
Incorporated ("Accredo") and issued a special dividend to its shareholders as
further described in Note 3. The operating results of the SPS business through
the closing date of the sale to Accredo, including corporate expenses directly
attributable to SPS operations, restructuring and special charges related to the
SPS business, as well as the gain on the sale, net of transaction costs and
related income taxes, are reflected as discontinued operations in the
accompanying consolidated statements of operations.
The Company adopted the provisions of Statement of Financial
Accounting Standard ("SFAS") No. 142, "Goodwill and Other Intangible Assets" as
of the beginning of fiscal 2002. In connection with this adoption, the Company
recorded a non-cash charge, net of taxes, as a cumulative effect of accounting
change in the accompanying consolidated statement of operations in fiscal 2002
as described in Note 2.
NOTE 2. SUMMARY OF CRITICAL AND OTHER SIGNIFICANT ACCOUNTING POLICIES
CONSOLIDATION
The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiaries. All significant intercompany balances
and transactions have been eliminated. The Company's fiscal year ends on the
Sunday nearest to December 31st, which was December 28, 2003 for fiscal 2003,
December 29, 2002 for fiscal 2002 and December 30, 2001 for fiscal 2001.
ESTIMATES
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
estimates and assumptions and select accounting policies that affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Actual results could
differ from those estimates.
The most critical estimates relate to revenue recognition, the
collectibility of accounts receivable and related reserves, the cost of claims
incurred but not reported, obligations under workers compensation, professional
liability and employee health and welfare insurance programs and Medicare
settlement issues.
A description of the critical and other significant accounting
policies and a discussion of the significant estimates and judgments associated
with such policies are described below.
CRITICAL ACCOUNTING POLICIES
REVENUE RECOGNITION
Under fee-for-service agreements with patients and commercial and
certain government payors, net revenues are recorded based on net realizable
amounts to be received in the period in which the services and products are
provided or delivered. Fee-for-service contracts with commercial payors are
traditionally one year in term and renewable automatically on an annual basis,
unless terminated by either party.
Under capitated arrangements with certain managed care customers, net
revenues are recognized based on a predetermined monthly contractual rate for
each member of the managed care plan regardless of the ser-
F-7
vices provided. Net revenues generated under capitated agreements were
approximately 16 percent, 16 percent, and 15 percent of total net revenues for
fiscal 2003, 2002, 2001, respectively.
Under the Prospective Payment System ("PPS") for Medicare
reimbursement, net revenues are recorded based on a reimbursement rate which
varies based on the severity of the patient's condition, service needs and
certain other factors; revenue is recognized ratably over the period in which
services are provided. Revenue is subject to adjustment during this period if
there are significant changes in the patient's condition during the treatment
period or if the patient is discharged but readmitted to another agency within
the same 60 day episodic period. Medicare billings under PPS are initially
recognized as deferred revenue and are subsequently amortized into revenue over
an average patient treatment period. The process for recognizing revenue to be
recognized under the Medicare program is based on certain assumptions and
judgments, including the average length of time of each treatment as compared to
a standard 60 day episode, the appropriateness of the clinical assessment of
each patient at the time of certification and the level of adjustments to the
fixed reimbursement rate relating to patients who receive a limited number of
visits, have significant changes in condition or are subject to certain other
factors during the episode. Deferred revenue of approximately $5.2 million and
$4.4 million relating to the Medicare PPS program was included in other Medicare
liabilities in the consolidated balance sheets as of December 28, 2003 and
December 29, 2002, respectively.
Revenue adjustments result from differences between estimated and
actual reimbursement amounts, an inability to obtain appropriate billing
documentation or authorizations acceptable to the payor and other reasons
unrelated to credit risk. Revenue adjustments are deducted from gross accounts
receivable. These revenue adjustments are based on significant assumptions and
judgments which are determined by Company management based on historical trends.
Third party settlements resulting in recoveries are recognized as net revenues
in the period in which the funds are received.
Net revenues attributable to major payor sources of reimbursement are
as follows:
FISCAL YEAR
-----------------------------
2003 2002 2001
-------- -------- ---------
Medicare 22% 21% 21%
Medicaid and Other Government 20 22 23
Commercial Insurance and Other 58 57 56
--- --- ---
100% 100% 100%
=== === ===
The Company is party to a contract with CIGNA Health Corporation
("Cigna"), pursuant to which the Company provides or contracts with third party
providers to provide home nursing services, acute and chronic infusion
therapies, durable medical equipment, and respiratory products and services to
patients insured by Cigna. For fiscal years 2003, 2002 and 2001, Cigna accounted
for approximately 36 percent, 38 percent and 36 percent, respectively, of the
Company's total net revenues. The Company has extended its relationship with
Cigna by entering into a new national home health care contract, effective
January 1, 2004, with the new contract expiring on December 31, 2006. No other
commercial payor accounts for 10 percent or more of the Company's net revenues.
COLLECTIBILITY OF ACCOUNTS RECEIVABLE
The process for estimating the ultimate collection of receivables,
particularly with respect to fee-for-service arrangements, involves significant
assumptions and judgments. In this regard, the Company has implemented a
standardized approach to estimate and review the collectibility of its
receivables based on accounts receivable aging trends. Historical collection and
payor reimbursement experience is an integral part of the estimation process
related to determining the allowance for doubtful accounts. In addition, the
Company assesses the current state of its billing functions in order to identify
any known collection or reimbursement issues to determine the impact, if any, on
its reserve estimates, which involve judgment. Revisions in reserve estimates
are recorded as an adjustment to the provision for doubtful accounts which is
reflected in selling, general and administrative expenses in the consolidated
statements of operations. The Company believes that its collection and reserve
processes, along with the monitoring of its billing processes, help to reduce
the risk associated with material revisions to reserve estimates resulting from
adverse changes in collection, reimbursement experience and billing functions.
F-8
COST OF CLAIMS INCURRED BUT NOT REPORTED
Under capitated arrangements with managed care customers, the Company
estimates the cost of claims incurred but not reported based on applying
actuarial assumptions, historical patterns of utilization to authorized levels
of service, current enrollment statistics and other information. Under
fee-for-service arrangements with certain managed care customers, the Company
also estimates the cost of claims incurred but not reported and the estimated
revenue relating thereto in situations in which the Company is responsible for
care management and patient services are performed by a non-affiliated provider.
The estimate of cost of claims incurred but not reported involves
significant assumptions and judgments which relate to and may vary depending on
the services authorized at each of the Company's regional coordination centers,
historical patterns of service utilization and payment trends. These assumptions
and judgments are evaluated on a quarterly basis and changes in estimated
liabilities for costs of claims incurred but not reported are determined based
on such evaluation.
OBLIGATIONS UNDER INSURANCE PROGRAMS
The Company is obligated for certain costs under various insurance
programs, including workers compensation, professional liability and employee
health and welfare.
The Company may be subject to workers compensation claims and lawsuits
alleging negligence or other similar legal claims. The Company maintains various
insurance programs to cover this risk but is substantially self-insured for most
of these claims. The Company recognizes its obligations associated with these
programs in the period the claim is incurred. The cost of both reported claims
and claims incurred but not reported, up to specified deductible limits, have
generally been estimated based on historical data, industry statistics, the
Company's own home health specific historical claims experience, current
enrollment statistics and other information. Such estimates and the resulting
reserves are reviewed and updated periodically.
For the fiscal year ended December 29, 2002, the Company recorded a
special charge of $6.3 million relating primarily to a refinement in the
estimation process used to determine the Company's actuarially computed workers
compensation and professional liability reserves. Management believes that, as a
result of this refinement, sufficient data exists to allow the Company to more
heavily rely on its own home health specific historical claims experience in
determining the Company's estimates of workers compensation and professional
liability reserves. Previously the Company utilized insurance industry actuarial
information, as well as the Company's historical claims experience in developing
reserve estimates.
The Company maintains insurance coverage on individual claims. The
Company is responsible for the cost of individual workers compensation claims
and individual professional liability claims up to $500,000 per incident which
occurred prior to March 15, 2002 and $1,000,000 per incident thereafter. The
Company also maintains excess liability coverage relating to professional
liability and casualty claims which provides insurance coverage for individual
claims of up to $25,000,000 in excess of the underlying coverage limits.
Payments under the Company's workers compensation program are guaranteed by
letters of credit and segregated restricted cash balances.
The Company believes that its present insurance coverage and reserves
are sufficient to cover currently estimated exposures, but there can be no
assurance that the Company will not incur liabilities in excess of recorded
reserves or in excess of its insurance limits.
MEDICARE SETTLEMENT ISSUES
Prior to October 1, 2000, reimbursement of Medicare home care nursing
services was based on reasonable, allowable costs incurred in providing services
to eligible beneficiaries subject to both per visit and per beneficiary limits
in accordance with the Interim Payment System established through the Balanced
Budget Act of 1997. These costs were reported in annual cost reports which were
filed with the Centers for Medicare and Medicaid Services ("CMS") and were
subject to audit by the fiscal intermediary engaged by CMS. The fiscal
intermediary has not finalized its audit of the fiscal 2000 cost reports.
Furthermore, settled cost reports relating to certain years prior to fiscal 2000
could be subject to reopening of the audit process by the fiscal intermediary.
Although management believes that established reserves are sufficient, it is
possible that adjustments resulting from such audits could result in adjustments
to the consolidated financial statements that exceed established reserves.
F-9
OTHER SIGNIFICANT ACCOUNTING POLICIES
CASH, CASH EQUIVALENTS AND RESTRICTED CASH
The Company considers all investments with an original maturity of
three months or less on their acquisition date to be cash equivalents.
Restricted cash represents segregated cash funds in a trust account designated
as collateral under the Company's insurance programs. Interest on the trust
account funds accrue to the Company. The Company, at its option, may access the
cash funds in the trust account by providing equivalent amounts of alternative
security.
SHORT-TERM INVESTMENTS
The Company classifies investments with an original maturity of more
than three months and less than one year on the acquisition date as short-term
investments in accordance with SFAS No. 115 "Accounting for Certain Investments
in Debt and Equity Securities". Short-term investments are classified as "held
to maturity" investments and are reported at amortized cost which approximates
fair value.
FIXED ASSETS
Fixed assets, including costs of Company developed software, are
stated at cost and depreciated over the estimated useful lives of the assets
using the straight-line method. Leasehold improvements are amortized over the
shorter of the life of the lease or the life of the improvement.
GOODWILL AND OTHER INTANGIBLE ASSETS ("SFAS 142")
In June 2001, the Financial Accounting Standards Board ("FASB") issued
SFAS No. 142 "Goodwill and Other Intangible Assets" ("SFAS 142"), which broadens
the criteria for recording intangible assets separate from goodwill. SFAS 142
requires the use of a non-amortization approach to account for purchased
goodwill and certain intangibles. Under a non-amortization approach, goodwill
and certain intangibles are not amortized into results of operations, but
instead are reviewed for impairment and an impairment charge is recorded in the
periods in which the recorded carrying value of goodwill and certain intangibles
is more than its estimated fair value. The Company adopted SFAS 142 as of the
beginning of fiscal 2002. The provisions of SFAS 142 require that a transitional
impairment test be performed as of the beginning of the year the statement is
adopted.
Based on the results of the transitional impairment tests, the Company
determined that an impairment loss relating to goodwill had occurred and
recorded a non-cash charge of $187.1 million, net of a deferred tax benefit of
$30.2 million, as cumulative effect of accounting change in the accompanying
consolidated statement of operations for the fiscal year ended December 29,
2002. The deferred tax benefit was recorded by eliminating a deferred tax
liability of $26.8 million and recording a deferred tax asset of approximately
$39 million, offset by an increase in the tax valuation allowance by the same
amount. During fiscal 2002, the Company also recorded a tax benefit of
approximately $3.4 million relating to tax deductible goodwill. See Note 12 to
the consolidated financial statements.
For fiscal year 2001, intangibles, principally goodwill, associated
with acquired businesses were being amortized on a straight-line basis over
periods ranging from 10 to 40 years in accordance with APB Opinion No. 17,
"Intangible Assets" based on a fair value methodology.
The table below presents a reconciliation of reported net income to
adjusted net income as if SFAS 142 was adopted as of January 1, 2001 (in
thousands, except per share amounts):
F-10
FOR THE FISCAL YEAR ENDED
DECEMBER 30, 2001
-------------------------------
EARNINGS PER SHARE
NET INCOME BASIC AND DILUTED
---------- ------------------
Reported net income $ 20,988 $ 0.90
Add back: Goodwill amortization, net of tax 10,023 0.43
---------- --------
Adjusted net income $ 31,011 $ 1.33
========== ========
The provisions of SFAS 142 also require that a goodwill impairment
test be performed annually or on the occasion of other events that indicate a
potential impairment. The annual impairment test of goodwill was performed and
indicated that there was no impairment of goodwill as of December 28, 2003.
ACCOUNTING FOR IMPAIRMENT AND DISPOSAL OF LONG-LIVED ASSETS
The Company evaluates the possible impairment of its long-lived
assets, including intangible assets which are amortized pursuant to the
provisions of SFAS 142, under SFAS No. 144, "Accounting for Impairment or
Disposal of Long-Lived Assets" ("SFAS 144"). The Company reviews the
recoverability of its long-lived assets when events or changes in circumstances
occur that indicate that the carrying value of the asset may not be recoverable.
Evaluation of possible impairment is based on the Company's ability to recover
the asset from the expected future pretax cash flows (undiscounted and without
interest charges) of the related operations. If the expected undiscounted pretax
cash flows are less than the carrying amount of such asset, an impairment loss
is recognized for the difference between the estimated fair value and carrying
amount of the asset.
STOCK-BASED COMPENSATION PLANS
SFAS No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123"),
as amended by SFAS No. 148, "Accounting for Stock-Based Compensation -
Transition and Disclosure - an amendment of FASB No. 123" ("SFAS 148")
encourages, but does not require, companies to record compensation cost for
stock-based compensation plans at fair value. In addition, SFAS 148 provides
alternative methods of transition for a voluntary change to the fair value based
method of accounting for stock-based employee compensation, and amends the
disclosure requirements of SFAS 123 to require prominent disclosures in both
annual and interim financial statements about the method of accounting for
stock-based employee compensation and the effect of the method used on reported
results.
The Company has chosen to adopt the disclosure only provisions of SFAS
No. 148 and continues to account for stock-based compensation using the
intrinsic value method prescribed in Accounting Principles Board ("APB") Opinion
No. 25, "Accounting for Stock Issued to Employees" ("APB 25"), and related
interpretations. Under this approach, the imputed cost of stock option grants
and discounts offered under the Company's Employee Stock Purchase Plan ("ESPP")
is disclosed, based on the vesting provisions of the individual grants, but not
charged to expense. See Note 11.
EARNINGS PER SHARE
Basic and diluted earnings (loss) per share for each period presented
has been computed by dividing the net income (loss) by the weighted average
number of shares outstanding for each respective period. The computations of the
basic and diluted per share amounts for the Company's continuing operations were
as follows (in thousands, except per share amounts):
F-11
FOR THE FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- ----------------- -----------------
Income (loss) from continuing operations $ 56,766 $ (53,543) $ (13,910)
===========================================================================================================
Basic weighted average common
shares outstanding 26,262 26,183 23,186
Shares issuable upon the assumed exercise of
stock options and in connection with the ESPP
using the treasury stock method 1,177 - -
----------- ---------- -----------
Diluted weighted average common
shares outstanding 27,439 26,183 23,186
----------- ---------- -----------
===========================================================================================================
Income (loss) from continuing operations
per common share:
Basic $ 2.16 $ (2.05) $ (0.60)
Diluted $ 2.07 $ (2.05) $ (0.60)
===========================================================================================================
The weighted average number of shares outstanding of 23,186,000 for
fiscal year 2001 included 2,146,105 shares of common stock issued upon
conversion of $20 million of the 10 percent convertible preferred trust
securities from the date of conversion as discussed in Note 7.
For fiscal years 2002 and 2001, in accordance with SFAS No. 128
"Earnings Per Share," the number of common shares used in computing the diluted
earnings (loss) per share for continuing operations was used for discontinued
operations, cumulative effect of accounting change and net income (loss), even
though the impact was antidilutive.
The computation of diluted earnings (loss) per share from continuing
operations for fiscal year 2002 excluded an incremental 1,592,000 shares that
would be issuable upon the assumed exercise of stock options and in connection
with the ESPP using the treasury stock method, since their inclusion would be
antidilutive on earnings.
For fiscal year 2001, due to the antidilutive effect on loss from
continuing operations, the diluted earnings (loss) per share computation
excluded the effect of (i) an incremental 1,454,000 shares that would have been
issued if the 10 percent convertible preferred trust securities were converted
at the beginning of the year and (ii) 1,229,000 shares that would be issuable
upon the assumed exercise of stock options under the treasury stock method.
INCOME TAXES
The Company uses the asset and liability approach to account for
income taxes. Under this method, deferred tax assets and liabilities are
recognized for the expected future tax consequences of differences between the
carrying amounts of assets and liabilities and their respective tax bases using
tax rates in effect for the year in which the differences are expected to
reverse. The effect on deferred tax assets and liabilities of a change in tax
rates is recognized in income in the period when the change is enacted.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The fair value of a financial instrument represents the amount at
which the instrument could be exchanged in a current transaction between willing
parties, other than in a forced sale or liquidation. Significant differences can
arise between the fair value and carrying amount of financial instruments that
are recognized at historical amounts.
The carrying amounts of the Company's cash and cash equivalents,
restricted cash, short-term investments, accounts receivable, accounts payable
and certain other current liabilities approximate fair value because of their
short maturity.
F-12
DEBT ISSUANCE COSTS
The Company amortizes deferred debt issuance costs over the term of
its credit facility.
In April 2002, the FASB issued SFAS No. 145 "Rescission of FASB
Statements No. 4, 44 and 64, Amendment of FASB Statements No. 13, and Technical
Correction" ("SFAS 145"). SFAS 145 rescinded SFAS No. 4 "Reporting Gains and
Losses from Extinguishment of Debt" ("SFAS 4"), SFAS No. 44 "Accounting for
Intangible Assets of Motor Carriers" ("SFAS 44") and SFAS No. 64
"Extinguishments of Debt Made to Satisfy Sinking-Fund Requirements" ("SFAS 64")
and amended SFAS No. 13 "Accounting for Leases" ("SFAS 13"). This statement
updates, clarifies and simplifies existing accounting pronouncements. As a
result of rescinding SFAS 4 and SFAS 64, the criteria in APB Opinion No. 30
"Reporting the Results of Operations-Reporting the Effects of Disposal of a
Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring
Events and Transactions" will be used to determine whether gains and losses from
extinguishment of debt receive extraordinary item treatment. The Company adopted
SFAS 145, effective April 1, 2002. During the fiscal year ended December 29,
2002, the impact of this adoption resulted in the Company recognizing a
write-off of approximately $1.5 million of deferred debt issuance costs
associated with the terminated credit facility which is reflected in selling,
general and administrative expenses in the accompanying consolidated statement
of operations and is further discussed in Note 4.
RECLASSIFICATION
Certain reclassifications have been made to the 2002 and 2001
consolidated financial statements to conform to current year presentation.
RECENT ACCOUNTING PRONOUNCEMENTS
In July 2002, the FASB issued SFAS No. 146 "Accounting for Costs
Associated with Exit or Disposal Activities" ("SFAS 146"), which addresses the
recognition, measurement, and reporting of costs associated with exit or
disposal activities, and supersedes Emerging Issues Task Force ("EITF") Issue
No. 94-3 "Liability Recognition for Certain Employee Termination Benefits and
Other Costs to Exit An Activity (including Certain Costs Incurred in a
Restructuring)" ("EITF 94-3"). The principal difference between SFAS 146 and
EITF 94-3 relates to the requirements for recognition of a liability for a cost
associated with an exit or disposal activity. SFAS 146 requires that a liability
for a cost associated with an exit or disposal activity, including those related
to employee termination benefits and obligations under operating leases and
other contracts, be recognized when the liability is incurred, and not
necessarily the date of an entity's commitment to an exit plan, as under EITF
94-3. SFAS 146 also establishes that the initial measurement of a liability
recognized under SFAS 146 be based on fair value. The provisions of SFAS 146 are
effective for exit or disposal activities that are initiated after December 31,
2002, with early application encouraged. The Company adopted SFAS 146, effective
December 30, 2002. For exit or disposal activities initiated prior to December
30, 2002, the Company followed the accounting guidelines outlined in EITF 94-3.
In January 2003, the FASB issued Interpretation No. 46, "Consolidation
of Variable Interest Entities," as revised in December 2003 ("FIN 46"). FIN 46
requires a variable interest entity to be consolidated by a company if that
company is subject to a majority of the risk of loss from the variable interest
entity's activities or entitled to receive a majority of the entity's residual
returns or both. Historically, entities generally were not consolidated unless
the entity was controlled through voting interests. FIN 46 also requires
disclosures about variable interest entities that a company is not required to
consolidate but in which it has a significant variable interest. The
consolidation requirements of FIN 46 will apply to variable interest entities as
of March 31, 2004 for the Company. Also, certain disclosure requirements apply
to all financial statements issued after December 31, 2003, regardless of when
the variable interest entity was established. The adoption of this standard is
not expected to have a material impact on the Company's consolidated financial
statements.
NOTE 3. ACQUISITIONS AND DISPOSITIONS
ACQUISITION OF FIRST HOME CARE BUSINESS
On March 28, 2003, the Company completed the purchase of certain
assets and the business of First Home Care - Houston, Inc. and FHCH, Inc.
pursuant to an asset purchase agreement for cash consideration of $1.3 million.
The purchase price allocation consisted of goodwill of $1.2 million and assets
and other intangibles of $0.1 million.
F-13
SALE OF SPECIALTY PHARMACEUTICAL SERVICES BUSINESS
On June 13, 2002, the Company consummated the sale of its SPS business
to Accredo (the "SPS Sale"). The SPS Sale was effected pursuant to an asset
purchase agreement (the "Asset Purchase Agreement") dated January 2, 2002,
between Gentiva, Accredo and certain of Gentiva's subsidiaries named therein.
Pursuant to the terms of the Asset Purchase Agreement, Accredo
acquired the SPS business in consideration for:
o the payment to the Company of a cash amount equal to $207.5
million (before a $0.9 million reduction resulting from a closing
net book value adjustment); and
o 5,060,976 shares of Accredo common stock.
Based on the closing price of the Accredo common stock on June 13,
2002 ($51.89 per share), the value of the stock consideration was $262.6
million.
In connection with the SPS Sale, the Company's Board of Directors
declared a dividend, payable to shareholders of record on June 13, 2002, of all
the common stock consideration and substantially all the cash consideration
received from Accredo. The cash consideration received by the Company before the
closing net book value adjustment was $207.5 million; however, the amount
distributed to the Company's shareholders was reduced by $3.5 million to $204
million as a holdback for income taxes the Company expected to incur on the
proceeds received in excess of $460 million as detailed in the Company's proxy
statement, dated May 10, 2002. The special dividend, which was delivered to the
distribution agent on June 13, 2002 for payment to the Company's shareholders,
resulted in shareholders of record on the record date receiving $7.76 in cash
and 0.19253 shares of Accredo common stock (valued at $9.99 per share based on
the June 13, 2002 closing price of $51.89 per share of Accredo common stock) for
each share of Gentiva common stock held. The total value of the special dividend
amounted to $17.75 per share. Cash was paid in lieu of fractional shares.
In connection with the SPS sale, the Company incurred $16.2 million in
transaction costs which related to investment banking fees, legal and accounting
costs, change in control and other employee related payments and miscellaneous
other costs. SPS revenues and operating results for the periods presented were
as follows (in thousands):
FOR THE FISCAL YEAR ENDED
-------------------------------------
DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- -----------------
Net revenues $ 323,319 $ 648,110
========== ==========
Operating results of discontinued SPS business:
Income before income taxes $ 11,238 $ 43,588
Income tax expense (1,313) (8,690)
---------- ----------
Net income 9,925 34,898
---------- ----------
Gain on disposal of SPS business, including
transaction costs of $16.2 million for fiscal
year 2002 205,355 -
Income tax expense (23,702) -
---------- ----------
Gain on disposal, net of tax 181,653 -
---------- ----------
Discontinued operations, net of tax $ 191,578 $ 34,898
========== ==========
NOTE 4. RESTRUCTURING AND OTHER SPECIAL CHARGES
During fiscal 2002 and 2001, the Company recorded restructuring and
other special charges aggregating $46.1 million and $3.0 million, respectively.
F-14
FISCAL 2002
BUSINESS REALIGNMENT ACTIVITIES
The Company recorded charges of $6.8 million during the second quarter
ended June 30, 2002 in connection with a restructuring plan. This plan included
the closing and consolidation of seven field locations and the realignment and
consolidation of certain corporate and administrative support functions due
primarily to the sale of the Company's SPS business. These charges included
employee severance of $0.9 million relating to the termination of 115 employees
in field locations and certain corporate and administrative departments, and
future lease payments and other associated costs of $5.9 million resulting
principally from the consolidation of office space at the Company's corporate
headquarters and a change in estimated future lease obligations and other costs
in excess of sublease rentals relating to a lease for a subsidiary of the
Company's former parent company which the Company agreed to assume in connection
with its Split-Off in March 2000. These charges were reflected in selling,
general and administrative expenses in the accompanying consolidated statement
of operations for the fiscal year ended December 29, 2002. The major components
of the restructuring charges as well as the activity during fiscal years 2003
and 2002 were as follows (in thousands):
COMPENSATION
AND SEVERANCE FACILITY LEASE
COSTS AND OTHER COSTS TOTAL
--------------- ----------------- --------------
FISCAL 2002 CHARGE $ 920 $ 5,893 $ 6,813
Cash expenditures (726) (1,348) (2,074)
-------- --------- ---------
Balance at December 29, 2002 194 4,545 4,739
Cash expenditures (194) (2,239) (2,433)
-------- --------- ---------
Balance at December 28, 2003 $ - $ 2,306 $ 2,306
======== ========= =========
The balance of unpaid charges, which will be paid over the remaining
lease terms, was included in other accrued expenses in the consolidated balance
sheets.
OPTION TENDER OFFER
During the second quarter ended June 30, 2002, the Company effected a
cash tender offer for all outstanding options to purchase its common stock for
an aggregate option purchase price not to exceed $25 million. In connection with
this tender offer, the Company recorded a charge of $21.4 million during the
second quarter of fiscal 2002, which is reflected in selling, general and
administrative expenses in the accompanying consolidated statement of operations
for the fiscal year ended December 29, 2002.
SETTLEMENT COSTS
The Company recorded a $7.7 million charge in the second quarter of
fiscal 2002 to reflect settlement costs relating to the FREDRICKSON V. OLSTEN
HEALTH SERVICES CORP. AND OLSTEN CORPORATION lawsuit as well as estimated
settlement costs related to government inquiries regarding cost reporting
procedures concerning contracted nursing and home health aide costs (see Note
9). These costs are reflected in selling, general and administrative costs in
the accompanying consolidated statement of operations for the fiscal year ended
December 29, 2002.
INSURANCE COSTS
The Company recorded a special charge of $6.3 million in the second
quarter of fiscal 2002 related primarily to a refinement in the estimation
process used to determine the Company's actuarially computed workers
compensation and professional liability insurance reserves. This special charge
is reflected in cost of services sold in the accompanying consolidated statement
of operations for the fiscal year ended December 29, 2002.
F-15
ASSET WRITEDOWNS AND OTHER
The Company recorded charges of $3.8 million in the second quarter of
fiscal 2002, consisting primarily of a write-down of inventory and other assets
associated with home medical equipment used in the Company's nursing operations,
and a write-off of deferred debt issuance costs associated with the terminated
credit facility. The charges are reflected in selling, general and
administrative expenses in the accompanying consolidated statement of operations
for the fiscal year ended December 29, 2002.
FISCAL 2001
SETTLEMENT COSTS
The Company recorded special charges of approximately $3.0 million
during fiscal 2001 in connection with the settlement of the GILE V. OLSTEN
CORPORATION, ET AL., and the STATE OF INDIANA V. QUANTUM HEALTH RESOURCES, INC.
AND OLSTEN HEALTH SERVICES, INC. lawsuits and for various other legal costs.
These legal matters are further discussed in Note 9. These special charges are
reflected in selling, general and administrative expenses in the accompanying
consolidated statement of operations for the fiscal year ended December 30,
2001.
NOTE 5. FIXED ASSETS, NET
(IN THOUSANDS) USEFUL LIVES DECEMBER 28, 2003 DECEMBER 29, 2002
- ------------------------------- ------------ ----------------- -----------------
Computer equipment and software 3-5 Years $ 43,786 $ 44,582
Furniture and fixtures 5 Years 20,031 19,337
Leasehold improvements Lease Term 9,166 10,224
Machinery and equipment 5 Years 391 171
----------- -----------
73,374 74,314
Less accumulated depreciation (58,239) (61,289)
----------- -----------
$ 15,135 $ 13,025
=========== ===========
Depreciation expense relating to continuing operations was
approximately $6.9 million in fiscal 2003, $7.2 million in fiscal 2002 and $8.7
million in fiscal 2001.
NOTE 6. LONG-TERM DEBT
The Company's credit facility, which was entered into on June 13,
2002, as amended, as described below, provides up to $55 million in borrowings,
including up to $40 million which is available for letters of credit. The
Company may borrow up to a maximum of 80 percent of the net amount of eligible
accounts receivable, as defined, less any reasonable and customary reserves, as
defined, required by the lender. Borrowing availability under the credit
facility was reduced by $10 million until such quarter in 2003 in which the
trailing 12 month EBITDA, excluding certain restructuring costs and special
charges, as defined, exceeded $15 million. As of March 30, 2003, the trailing 12
month EBITDA threshold was achieved and the availability restriction lifted,
effective June 1, 2003.
At the Company's option, the interest rate on borrowings under the
credit facility was based on the London Interbank Offered Rates (LIBOR) plus
3.25 percent or the lender's prime rate plus 1.25 percent. In addition, the
Company was required to pay a fee equal to 2.5 percent per annum of the
aggregate face amount of outstanding letters of credit. Beginning in 2003, the
applicable margin for the LIBOR borrowing, prime rate borrowing and letter of
credit fees decreases by 0.25 percent to 3.0 percent, 1.0 percent, and 2.25
percent, respectively, provided that the Company's trailing 12 month EBITDA,
excluding certain restructuring costs and special charges, as defined, is in
excess of $20 million. The Company was also subject to an unused line fee equal
to 0.50 percent per annum of the average daily difference between the total
revolving credit facility amount and the total outstanding borrowings and
letters of credit. Beginning in 2003, the unused credit line fee decreases to
0.375 percent provided the minimum EBITDA target described above is achieved.
The higher margins and fees are subject to reinstatement in the event that the
Company's trailing 12 month EBITDA falls below $20 million. The Company met this
minimum EBITDA requirement as of March 30, 2003, with the rate reduction
effective June 1, 2003, and continued to meet this requirement as of December
28, 2003.
F-16
The credit facility, which expires in June 2006, includes certain
covenants requiring the Company to maintain a minimum tangible net worth of
$101.6 million, minimum EBITDA, as defined, and a minimum fixed charge coverage
ratio, as defined. Other covenants in the credit facility include limitation on
mergers, consolidations, acquisitions, indebtedness, liens, distributions
including dividends, capital expenditures, stock repurchases and dispositions of
assets and other limitations with respect to the Company's operations. On August
7, 2003, the Company's credit facility was amended to make covenants relating to
acquisitions and stock repurchases less restrictive, provided that the Company
maintains minimum excess aggregate liquidity, as defined in the amendment, equal
to at least $60 million, and to allow for the disposition of certain assets.
The credit facility further provides that if the agreement is
terminated for any reason, the Company must pay an early termination fee equal
to $275,000 if the facility is terminated during the period from June 13, 2003
to June 12, 2004 and $137,500 if the facility is terminated from June 13, 2004
to June 12, 2005. There is no fee for termination of the facility subsequent to
June 12, 2005. Loans under the credit facility are collateralized by all of the
Company's tangible and intangible personal property, other than equipment. As of
December 28, 2003, the Company was in compliance with these covenants.
Total outstanding letters of credit were approximately $20.8 million
at December 28, 2003 and $27.6 million at December 29, 2002. The letters of
credit, which expire one year from date of issuance, were issued to guarantee
payments under the Company's workers compensation program and for certain other
commitments. There were no borrowings outstanding under the credit facility as
of December 28, 2003.
During fiscal year 2003, the Company entered into a trust agreement
and segregated $21.8 million of cash funds in a trust account to provide
additional collateral and to replace approximately $7 million of letters of
credit and a $5 million surety bond which had been used as collateral under the
Company's insurance programs. These funds are reported as restricted cash in the
accompanying consolidated balance sheet as of December 28, 2003. Interest on the
funds in the trust account accrues to the Company. The Company, at its option,
may access the cash funds in the trust account by providing equivalent amounts
of alternative security, including letters of credit and surety bonds.
The Company has no other off-balance sheet arrangements and has not
entered into any transactions involving unconsolidated, limited purpose entities
or commodity contracts.
Net interest income was approximately $0.4 million for the fiscal year
ended December 28, 2003 and $0.8 million for the fiscal year ended December 29,
2002. Net interest income represented interest income of approximately $1.5
million for fiscal 2003 and $2.4 million for fiscal 2002, partially offset by
fees relating to the revolving credit facility and outstanding letters of
credit.
NOTE 7. MANDATORILY REDEEMABLE AND OTHER SECURITIES
GENTIVA OBLIGATED MANDATORILY REDEEMABLE PREFERRED SECURITIES OF A SUBSIDIARY
TRUST
On March 15, 2000, certain of the Company's and Olsten's directors,
officers and management and other related parties and other investors purchased
$20 million of 10 percent convertible trust preferred securities issued by a
Trust, of which the Company owned all the common equity. Simultaneously and in
connection with the issuance by the Trust of the convertible trust preferred
securities, the Company issued to the Trust $20 million of its 10 percent
convertible subordinated debentures. The convertible preferred trust securities
were mandatorily redeemable on March 15, 2005 and optionally redeemable after
March 15, 2001 at a declining premium over face amount. The convertible
subordinated debentures had the same terms as the convertible trust preferred
securities, including, but not limited to, maturity, interest, conversion and
redemption price.
The Trust which issued the convertible trust preferred securities was
a special purpose trust. The Trust's operations were limited to issuing the
convertible trust preferred securities and holding the Company's convertible
subordinated debentures. The Trust could pay dividends only to the extent that
the Company paid interest on its convertible subordinated debentures.
If the Company announced the redemption of its convertible
subordinated debentures and, as a result, the Trust intended to redeem the
convertible preferred trust securities, the holders of the preferred trust
securities had the option to convert their securities into the Company's common
stock at a conversion price of $9.319219 until two days before the scheduled
redemption date.
F-17
On August 7, 2001, the Company's Board of Directors authorized the
Company to call for the redemption of its 10 percent convertible subordinated
debentures on or about September 14, 2001 at a redemption price of 108 percent
of the original principal amount of the debentures in accordance with the terms
of an Indenture dated March 15, 2000, between the Company and Wilmington Trust
Company. All of the holders of the preferred trust securities opted to convert
their securities into the Company's common stock. During fiscal year 2001, the
Company issued 2,146,105 shares of common stock upon the conversion of $20
million of the convertible preferred trust securities. No convertible preferred
trust securities remained outstanding for redemption.
CUMULATIVE PREFERRED STOCK
The Company's authorized capital stock includes 25,000,000 shares of
preferred stock, $.01 par value, of which 1,000 shares have been designated
Series A Cumulative Non-voting Redeemable Preferred Stock ("cumulative preferred
stock"). On March 10, 2000, 100 shares of cumulative preferred stock were issued
for proceeds of $100,000. Holders of the cumulative preferred stock were
entitled to receive cumulative cash dividends at an annual rate of LIBOR plus 2
percent on the stated liquidation preference of $1,000 per share, payable
quarterly in arrears out of assets legally available for payment of dividends.
The shares of preferred stock that were issued on March 10, 2000 were redeemed
on June 12, 2002 at a redemption price of $1,000 per share.
NOTE 8. SHAREHOLDERS' EQUITY
On May 16, 2003, the Company announced that its Board of Directors had
authorized the Company to repurchase and formally retire up to 1,000,000 shares
of its outstanding common stock. The repurchases were to occur periodically in
the open market or through privately negotiated transactions based on market
conditions and other factors. As of July 23, 2003, the Company had repurchased
the authorized 1,000,000 shares of its common stock at an average cost of $9.08
per share and a total cost of approximately $9.1 million.
On August 7, 2003, the Company's Board of Directors authorized the
Company to repurchase and formally retire up to an additional 1,500,000 shares
of its outstanding common stock. The repurchases will occur periodically in the
open market or through privately negotiated transactions based on market
conditions and other factors. As of December 28, 2003, the Company had
repurchased 438,464 shares at an average cost of $12.18 per share and a total
cost of approximately $5.3 million.
NOTE 9. LEGAL MATTERS
LITIGATION
In addition to the matters referenced in this Note 9, the Company is
party to certain legal actions arising in the ordinary course of business
including legal actions arising out of services rendered by its various
operations, personal injury and employment disputes.
COOPER V. GENTIVA CARECENTRIX, INC. T/A/D/B/A/ GENTIVA HEALTH
SERVICES, U.S. District Court (W.D. Penn), Civil Action No. 01-0508. On January
2, 2002, this amended complaint was served on the Company alleging that the
defendant submitted false claims to the government for payment in violation of
the Federal False Claims Act, 31 U.S.C. 3729 et seq., and that the defendant had
wrongfully terminated the plaintiff. The plaintiff claimed that infusion pumps
delivered to patients did not supply the full amount of medication, allegedly
resulting in substandard care. Based on a review of the court's docket sheet,
the plaintiff filed a complaint under seal in March 2001. In October 2001, the
United States government filed a notice with the court declining to intervene in
this matter, and on October 24, 2001, the court ordered that the seal be lifted.
The Company filed its responsive pleading on February 25, 2002, and discovery
has now commenced. The Company has denied the allegations of wrongdoing in the
complaint and is defending itself vigorously in this matter. On May 19, 2003,
the Company filed a motion for summary judgment on the issue of liability. On
February 6, 2004, the court granted partial summary judgment for the Company,
dismissing two of the three claims alleged under the False Claims Act and
denying summary judgment for the Company on the wrongful termination claim. The
parties are completing discovery; therefore, the Company cannot determine a
range of damages, if any, at this time.
Other litigation matters that were settled in fiscal 2002 and 2001 are
discussed below.
FISCAL 2002
F-18
FREDRICKSON V. OLSTEN HEALTH SERVICES CORP. AND OLSTEN CORPORATION,
Case No. 01C.A.116, Court of Appeals, Seventh Appellate District, Mahoning
County, Ohio. In November 2000, the jury in this age-discrimination lawsuit
returned a verdict in favor of the plaintiff against Olsten consisting of
$675,000 in compensatory damages, $30 million in punitive damages and an
undetermined amount of attorneys' fees. The jury found that, although Olsten had
lawfully terminated the plaintiff's employment, its failure to transfer or
rehire the plaintiff rendered Olsten liable to the plaintiff. Following
post-trial motion practice by both parties, the trial court, in May 2001, denied
all post-trial motions, and entered judgment for the plaintiff for the full
amount of compensatory and punitive damages, and awarded the plaintiff reduced
attorney's fees of $247,938. In June 2001, defendants timely filed a Notice of
Appeal with the Court of Appeals, and the Company posted a supersedeas bond for
the full amount of the judgment, plus interest. This matter has been settled,
and settlement costs were recorded as part of special charges during the second
quarter of fiscal 2002 (see Note 4). The supersedeas bond was released and the
restricted cash of $35.2 million was released to the Company in September 2002.
FISCAL 2001
In GILE V. OLSTEN CORPORATION, ET AL., U.S. District Court for the
Central District of California, No. 97-9363-NM, plaintiff filed an age
discrimination suit against Olsten Corporation, Olsten Health Services, and a
certain individual in December 1997. The defendants denied the allegations of
discrimination on the basis that plaintiff's termination was part of a reduction
in force. The individual defendant was dismissed from the action, and the
remaining corporate defendants filed a motion for summary judgment that was
granted by the District Court in February 1999. The plaintiff appealed the
District Court's order to the Ninth Circuit Court of Appeals and in December
2000, the Court of Appeals issued its ruling which reversed the District Court
and remanded the case for trial. On or about June 19, 2001, the Company and the
plaintiff agreed to settle this matter and entered into a confidential
settlement agreement with full release.
In July 1999, the Indiana Attorney General's Office filed a lawsuit
against Olsten in Indiana Superior Court, captioned STATE OF INDIANA V. QUANTUM
HEALTH RESOURCES, INC. AND OLSTEN HEALTH SERVICES, Inc., No. 49D029907CP001011,
alleging that Olsten was overpaid by Medicaid, failed to properly disclose
information to Medicaid and engaged in improper billing. The alleged violations
predated Olsten's acquisition of Quantum Health Resources in June 1996. The
lawsuit sought unspecified monetary damages, double or treble damages, penalties
and investigative costs. The parties resolved this matter during fiscal 2001
pursuant to a confidential settlement agreement and full release. There is no
ongoing obligation on the part of the Company arising from this settlement.
INDEMNIFICATIONS
In connection with the Split-Off, the Company agreed to assume, to the
extent permitted by law, and to indemnify Olsten for, the liabilities, if any,
arising out of the above proceedings and other liabilities arising out of the
home health services business, including any such liabilities arising after the
Split-Off in connection with the government matters described below.
In addition, the Company and Accredo have agreed to indemnify each
other for breaches of representations and warranties of such party or the
non-fulfillment of any covenant or agreement of such party in connection with
the sale of the specialty pharmaceutical services business. The Company has also
agreed to indemnify Accredo for the retained liabilities and for tax
liabilities, and Accredo has agreed to indemnify the Company for assumed
liabilities and the operation of the SPS business after the closing of the
acquisition. The representations and warranties generally survive for the period
of two years after the closing of the acquisition, which occurred on June 13,
2002, except that:
o representations and warranties related to health care compliance
survive for three years after the closing of the acquisition;
o representations and warranties related to title of the assets and
sufficiency of assets and employees survive for the applicable
statute of limitations period; and
o representations and warranties related to tax matters survive
until thirty days after the expiration of the applicable tax
statute of limitations period, including any extensions of the
applicable period, subject to certain exceptions.
F-19
Accredo and the Company may recover indemnification for a breach of a
representation or warranty only to the extent a party's claim exceeds $1 million
for any individual claim or exceeds $5 million in the aggregate, subject to
certain conditions and only up to a maximum amount of $100 million.
These indemnification rights are the exclusive remedy from and after
the closing of the acquisition, except for the right to seek specific
performance of any of the agreements in the related asset purchase agreement, in
any case where a party is guilty of fraud in connection with the acquisition,
and with respect to tax liabilities and obligations.
On May 6, 2003, the Company received correspondence from Accredo
giving the Company notice of Accredo's indemnification rights for any breach
under the asset purchase agreement related to the adequacy of the accounts
receivable reserves in accordance with section 8.3 of the asset purchase
agreement; however, no breach of a representation or warranty was asserted
against the Company in the correspondence.
GOVERNMENT MATTERS
PRRB APPEAL
As further described in the Critical Accounting Policies section in
Note 2, the Company's annual cost reports, which were filed with the CMS, were
subject to audit by the fiscal intermediary engaged by CMS. In connection with
the audit of the Company's 1997 cost reports, the Medicare fiscal intermediary
made certain audit adjustments related to the methodology used by the Company to
allocate a portion of its residual overhead costs. The Company filed cost
reports for years subsequent to 1997 using the fiscal intermediary's
methodology. The Company believed its methodology used to allocate such overhead
costs was accurate and consistent with past practice accepted by the fiscal
intermediary; as such, the Company filed appeals with the Provider Reimbursement
Review Board ("PRRB") concerning this issue with respect to cost reports for the
years 1997, 1998 and 1999. The Company's consolidated financial statements for
the years 1997, 1998 and 1999 had reflected use of the methodology mandated by
the fiscal intermediary.
In June 2003, the Company and its Medicare fiscal intermediary signed
an Administrative Resolution relating to the issues covered by the appeals
pending before the PRRB. Under the terms of the Administrative Resolution, the
fiscal intermediary agreed to reopen and adjust the Company's cost reports for
the years 1997, 1998 and 1999 using a modified version of the methodology used
by the Company prior to 1997. This modified methodology will also be applied to
cost reports for the year 2000, which are currently under audit. The
Administrative Resolution required that the process to (i) reopen all 1997 cost
reports, (ii) determine the adjustments to allowable costs through the issuance
of Notices of Program Reimbursement ("NPRs") and (iii) make appropriate payments
to the Company, be completed in early 2004. Cost reports relating to years
subsequent to 1997 will be reopened after the process for the 1997 cost reports
is completed.
On February 17, 2004, the fiscal intermediary notified the Company
that it had completed the reopening of all 1997 cost reports and determined that
the adjustment to allowable costs for that year approximated $9 million. As of
February 27, 2004, the majority of the funds relating to this adjustment had
been remitted to the Company; the settlement amount will be recorded as net
revenues during the first quarter of fiscal 2004.
Although the Company believes that it could recover additional funds
as a result of applying the modified methodology discussed above to cost reports
subsequent to 1997, the settlement amounts cannot be specifically determined
until the reopening or audit of each year's cost reports is completed. This is
not expected to occur until the second half of fiscal 2004 or fiscal 2005.
However, in view of changes in reimbursement and the Company's operations in
periods subsequent to 1997, it is likely that future recoveries relating to any
cost report year from 1998 to 2000 will be significantly less than the 1997
settlement.
SUBPOENAS
On April 17, 2003, the Company received a subpoena from the Department
of Health and Human Services, Office of the Inspector General, Office of
Investigations ("OIG"). The subpoena seeks information regarding the Company's
implementation of settlements and corporate integrity agreements entered into
with the government, as well as the Company's treatment on cost reports of
employees engaged in sales and marketing efforts. With respect to the cost
report issues, the government has preliminarily agreed to narrow the scope of
production to the period from January 1, 1998 through September 30, 2000. On
February 17, 2004, the Company received a subpoena from the U.S. Department of
Justice ("DOJ") seeking additional information related to
F-20
the matters covered by the OIG subpoena. The Company has provided documents and
other information requested by the OIG pursuant to its subpoena and similarly
intends to cooperate fully with the DOJ subpoena as well as any future OIG or
DOJ information requests. To the Company's knowledge, the government has not
filed a complaint against the Company.
In February 2000, the Company received a document subpoena from the
Department of Health and Human Services, Office of the Inspector General, Office
of Investigations. The subpoena related to its agencies' cost reporting
procedures concerning contracted nursing and home health aide costs. This matter
has been settled and settlement costs were recorded as part of special charges
during the second quarter of fiscal 2002. (See Note 4).
NOTE 10. COMMITMENTS
The Company rents certain properties under non-cancelable, long-term
operating leases, which expire at various dates. Certain of these leases require
additional payments for taxes, insurance and maintenance and, in many cases,
provide for renewal options. Rent expense under all leases was $15.3 million in
2003, $16.2 million in 2002 and $18.5 million in 2001.
Future minimum rental commitments and sublease rentals for all
non-cancelable leases having an initial or remaining term in excess of one year
at December 28, 2003, are as follows (in thousands):
FISCAL YEAR TOTAL COMMITMENT SUBLEASE RENTALS NET
----------- ---------------- ---------------- ---------
2004 $ 18,936 $ 1,783 $ 17,153
2005 14,535 1,747 12,788
2006 10,190 1,058 9,132
2007 5,764 898 4,866
2008 2,888 158 2,730
Thereafter 2,822 - 2,822
In addition, the Company has purchase obligations due in fiscal 2004
of approximately $1.1 million.
NOTE 11. STOCK PLANS
In 1999, the Company adopted the 1999 Stock Incentive Plan ("1999
Plan") under which 5 million shares of common stock were reserved for issuance
upon exercise of options thereunder. The maximum total number of shares of
common stock for which grants may be made to any employee, consultant or
director under the 1999 plan in any calendar year is 300,000. These options may
be awarded in the form of incentive stock options ("ISOs") or non-qualified
stock options ("NQSOs"). The option price of an ISO and NQSO cannot be less than
100 percent and 85 percent, respectively, of the fair market value at the date
of grant. As of December 28, 2003, the Company had 1,476,698 shares available
for issuance under the 1999 Plan.
In 1999, the Company adopted the Stock & Deferred Compensation Plan
for Non-Employee Directors, which provided for payment of annual retainer fees
to non-employee directors, up to 50 percent of which such directors might elect
to receive in cash and the remainder of which would be paid in the form of
shares of common stock of the Company and also allowed deferral of such payment
of shares until termination of director's service. The plan was amended and
restated on January 1, 2004 and now provides for the deferral of annual retainer
fees under the plan only into stock units which are to be paid to non-employee
directors as shares of the Company's common stock upon termination of a
director's service. The total number of shares of common stock reserved for
issuance under this plan is 150,000, of which 81,441 shares were available for
future grants as of December 28, 2003. During fiscal 2003, 2002 and 2001, the
Company issued 7,575 shares, 11,928 shares and 3,370 shares, respectively, under
the plan. As of December 28, 2003, 36,246 shares were deferred.
In 1999, the Company adopted an employee stock purchase plan ("ESPP").
All employees of the Company, who have been employed for at least eight months
and whose customary employment exceeds twenty hours per week, are eligible to
purchase stock under this plan. The Compensation, Corporate Governance and
Nominating Committee of the Company's Board of Directors administers the plan
and has the power to determine the terms and conditions of each offering of
common stock. The purchase price of the shares under the plan is the lesser of
85 percent of the fair market value of the Company's common stock on the first
business day or the last business day of the six month offering period.
Employees may purchase shares having a fair market
F-21
value of up to $25,000 per calendar year. The maximum number of shares of common
stock that may be sold to any employee in any offering, however, will generally
be 10 percent of that employee's compensation during the period of the offering.
A total of 1,200,000 shares of common stock are reserved for issuance under the
employee stock purchase plan, of which 498,534 shares were available for future
issuance as of December 28, 2003. During fiscal 2003, 2002 and 2001, the Company
issued 280,664 shares, 166,003 shares and 112,014 shares, respectively, under
the plan.
Effective with the sale of the SPS business, the Company commenced a
cash tender offer for all of the outstanding options to purchase its common
stock. The tender offer resulted in 1,253,141 options being tendered and
accepted by the Company with 463,829 options remaining outstanding. To preserve
the aggregate intrinsic value of the options, the outstanding options were
converted to new Gentiva options at the ratio of 1 to 3.369, resulting in
converted options of 1,562,646. The exercise price of a new Gentiva stock option
represented 29.7 percent of the corresponding option, pre-conversion.
A summary of Gentiva stock options for fiscal 2003, fiscal 2002 and
fiscal 2001 is presented below:
2003 2002 2001
--------------------------- --------------------------- ---------------------------
WEIGHTED WEIGHTED WEIGHTED
STOCK AVERAGE STOCK AVERAGE STOCK AVERAGE
OPTIONS EXERCISE PRICE OPTIONS EXERCISE PRICE OPTIONS EXERCISE PRICE
--------- -------------- ---------- -------------- ---------- --------------
Options outstanding, beginning of year 2,549,667 $ 4.75 2,346,600 $ 8.61 3,689,006 $ 6.09
Granted 740,900 8.85 1,152,700 7.54 939,000 13.22
Exercised (452,338) 2.12 (665,040) 7.73 (2,156,796) 6.22
Cancelled/forfeitures (151,933) 7.99 (594,098) 8.52 (124,610) 10.04
Tendered options - - (1,253,141) 8.54 - -
Converted to new Gentiva options - - 1,562,646 2.63 - -
--------- -------- ---------- -------- ---------- ---------
Options outstanding, end of year 2,686,296 $ 6.14 2,549,667 $ 4.75 2,346,600 $ 8.61
========= ======== ========== ======== ========== =========
Options exercisable, end of year 1,345,570 $ 4.07 1,421,567 $ 2.53 838,168 $ 5.82
========= ======== ========== ======== ========== =========
The following table summarizes information about Gentiva stock options
outstanding at December 28, 2003:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
-------------------------------------------- -----------------------
NUMBER WEIGHTED WEIGHTED NUMBER WEIGHTED
AT AVERAGE AVERAGE AT AVERAGE
DECEMBER 28, EXERCISE REMAINING DECEMBER 28, EXERCISE
RANGE OF EXERCISE PRICE 2003 PRICE CONTRACTUAL LIFE 2003 PRICE
- ----------------------- -------------- -------- ---------------- ------------ --------
$1.07 to $1.30 54,234 $ 1.22 4.74 54,234 $ 1.22
$1.65 to $1.74 380,281 1.69 6.20 380,281 1.69
$2.02 to $2.95 59,454 2.27 3.02 59,454 2.27
$3.55 to $3.91 493,527 3.89 6.86 493,527 3.89
$7.50 to $7.50 956,800 7.50 8.46 330,873 7.50
$8.10 to $8.60 63,100 8.44 8.67 27,201 8.38
$8.74 to $9.75 678,900 8.86 9.06 - -
--------- ------- ---- --------- -------
$1.07 to $9.75 2,686,296 $ 6.14 7.81 1,345,570 $ 4.07
========= ======= ==== ========= =======
The Company has chosen to adopt the disclosure only provisions of SFAS
148 and continue to account for stock-based compensation using the intrinsic
value method prescribed in APB 25, and related interpretations. Under this
approach, the cost of restricted stock awards is expensed over their vesting
period, while the imputed cost of stock option grants and discounts offered
under the Company's ESPP is disclosed, based on the vesting provisions of the
individual grants, but not charged to expense.
The weighted average fair values of the Company's stock options,
granted during 2003, 2002 and 2001, calculated using the Black-Scholes option
pricing model, and other assumptions are as follows:
F-22
FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- ----------------- -----------------
Risk-free interest rate 3.51% 4.15% 4.88%
Expected volatility 60% 38% 65%
Expected life 6 years 5 years 5 years
Contractual life 10 years 10 years 10 years
Expected dividend yield 0% 0% 0%
Weighted average fair value
of options granted $ 5.24 $ 3.02 $ 7.76
Pro forma compensation expense is calculated for the fair value of the
employee's purchase rights, under the ESPP, using the Black-Scholes model.
Assumptions for the fiscal 2003 and fiscal 2002 are as follows:
FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002
--------------------------- ---------------------------
1ST OFFERING 2ND OFFERING 1ST OFFERING 2ND OFFERING
PERIOD PERIOD PERIOD PERIOD
------------ ------------ ------------ ------------
Risk-free interest rate: 1.25% 0.97% 1.89% 1.77%
Expected volatility 32% 29% 60% 60%
Expected life 0.5 years 0.5 years 0.5 years 0.5 years
Expected dividend yield 0% 0% 0% 0%
The following table presents net income (loss) and basic and diluted
earnings (loss) per common share, had the Company elected to recognize
compensation cost based on the fair value at the grant dates for stock option
awards and discounts granted for stock purchases under the Company's ESPP,
consistent with the method prescribed by SFAS 123, as amended by SFAS 148:
FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- ----------------- -----------------
Net income (loss) - as reported $ 56,766 $ (49,033) $ 20,988
Add: Stock-based employee compensation
expense included in reported net income, net of tax - 13,160 -
Deduct: Total stock-based compensation expense
determined under fair value based method for
all awards, net of tax (1,575) (5,022) (3,002)
----------- ---------- -----------
Net income (loss) - pro forma $ 55,191 $ (40,895) $ 17,986
=========== ========== ===========
Basic income (loss) per share - as reported $ 2.16 $ (1.87) $ 0.90
Basic income (loss) per share - pro forma $ 2.10 $ (1.56) $ 0.78
Diluted income (loss) per share - as reported $ 2.07 $ (1.87) $ 0.90
Diluted income (loss) per share - pro forma $ 2.01 $ (1.56) $ 0.78
On December 31, 2003, the Company issued 992,100 stock options at an
exercise price of $12.87 per share and issued 125,039 shares under its ESPP.
NOTE 12. INCOME TAXES
Comparative analyses of the provision (benefit) for income taxes
follows (in thousands):
F-23
FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- ----------------- -----------------
Current
Federal $ - $ 5,600 $ (6,632)
State and local 1,567 - (183)
----------- ---------- -----------
1,567 5,600 (6,815)
----------- ---------- -----------
Deferred
Federal (31,875) 10,114 -
State and local (3,160) 2,723 -
----------- ---------- -----------
(35,035) 12,837 -
----------- ---------- -----------
Provision for income taxes $ (33,468) $ 18,437 $ (6,815)
=========== ========== ===========
A reconciliation of the differences between income taxes computed at
federal statutory rate and provisions (benefits) for income taxes for each year
are as follows (in thousands):
FISCAL YEAR ENDED
---------------------------------------------------------
DECEMBER 28, 2003 DECEMBER 29, 2002 DECEMBER 30, 2001
----------------- ----------------- -----------------
Income taxes computed at Federal statutory tax rate $ 8,162 $ (12,287) $ (7,254)
State income taxes, net of Federal benefit 1,019 (1,770) (119)
Nondeductible meals and entertainment 167 155 232
Income tax audit adjustments (177) 5,439 -
Deferred rate differential 1,142 - -
Decrease in Federal valuation allowance (44,438) - -
Valuation allowance adjustment for adoption of SFAS 142 - 26,859 -
Amortization of intangibles - - 623
Other 657 41 (297)
---------- ----------- --------
$ (33,468) $ 18,437 $ (6,815)
========== =========== ========
The federal income tax rate reconciliation schedule above includes only
components associated with continuing operations.
Deferred tax assets and deferred tax liabilities are as follows (in
thousands):
DECEMBER 28, 2003 DECEMBER 29, 2002
----------------- -----------------
Deferred tax assets
Reserves and allowances $ 21,290 $ 24,543
Net operating loss and other carryforwards (Federal and state) 4,966 5,993
Intangible assets 29,085 33,202
Depreciation 23 332
Other 208 574
Less: Valuation allowance - (63,892)
---------- ----------
Total deferred tax assets 55,572 752
Deferred tax liabilities
Capitalized software (1,083) (752)
---------- ----------
Net deferred tax assets $ 54,489 $ -
========== ==========
At December 28, 2003, net deferred tax assets of $26.5 million and
$28.0 million were recorded in current assets and noncurrent assets,
respectively, in the accompanying consolidated balance sheet. At December 29,
2002, deferred tax assets of $0.8 million were included in current assets and
deferred tax liabilities of $0.8 million were included in other liabilities in
the consolidated balance sheet.
The Company had maintained a valuation allowance for its deferred tax
assets as of December 29, 2002 since the absence of historical pre-tax income
created uncertainty about the Company's ability to realize tax benefits in
future years. During the interim periods of fiscal 2003, a portion of the
valuation allowance ($9.4 million) was utilized to offset a corresponding
decrease in net deferred tax assets. The remaining valuation allowance was
reversed at the end of fiscal 2003 based on management's belief that it is more
likely than not that all of the Company's net deferred tax assets will be
realized due to the Company's achieved earnings trends and outlook. In this
regard, $35.0 million was recorded as an income tax benefit in the accompanying
statement of
F-24
operations for fiscal 2003 and $19.5 million was credited directly to
shareholders' equity at December 28, 2003 to reflect the portion of the
valuation allowance associated with stock compensation tax benefits.
As of December 28, 2003, the Company's net operating losses and tax
credit carryforwards for income tax purposes were approximately $11.1 million
and $0.7 million, respectively.
Income tax payments, including payments associated with discontinued
operations, were $1.6 million, $7.6 million and $0.7 million for fiscal years
2003, 2002 and 2001, respectively.
NOTE 13. BENEFIT PLANS FOR PERMANENT EMPLOYEES
The Company maintains qualified and non-qualified defined contribution
retirement plans for its salaried employees, which provide for a partial match
of employee savings under the plans and for discretionary profit-sharing
contributions based on employee compensation. With respect to the Company's
non-qualified defined contribution retirement plan for salaried employees, all
pre-tax contributions, matching contributions and profit sharing contributions
(and the earnings therein) are held in a Rabbi Trust and are subject to the
claims of the general, unsecured creditors of the Company. All post-tax
contributions are held in a secular trust and are not subject to the claims of
the creditors of the Company. The fair value of the assets held in the Rabbi
Trust and the liability to plan participants as of December 28, 2003 and
December 29, 2002 totaling approximately $10.0 million and $9.0 million,
respectively, are included in other assets and other liabilities on the
accompanying consolidated balance sheets.
Company contributions under the defined contribution plans were
approximately $1.8 million in 2003, $2.0 million in 2002 and $2.7 million in
2001.
F-25
NOTE 14. QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
(in thousands, except per share amounts)
FIRST SECOND THIRD FOURTH
QUARTER QUARTER QUARTER QUARTER
--------- --------- --------- ---------
YEAR ENDED DECEMBER 28, 2003
Net revenues $ 202,016 $ 208,446 $ 199,698 $ 203,869
Gross profit 68,766 69,624 69,241 74,411
Net income 5,201 5,247 4,547 41,771(1)
Earnings Per Share:
Net income - basic 0.19 0.20 0.18 1.62
Net income - diluted 0.19 0.19 0.17 1.53
Weighted average shares outstanding:
Basic 26,696 26,530 25,972 25,852
Diluted 27,772 27,490 27,098 27,225
FIRST SECOND THIRD FOURTH
QUARTER QUARTER QUARTER QUARTER
--------- --------- --------- ---------
YEAR ENDED DECEMBER 29, 2002
Net revenues $ 192,799 $ 195,623 $ 188,443 $ 191,636
Gross profit 63,613 56,731 (2) 63,545 63,711
Income (loss) from continuing operations (25,914) (33,678)(2) 2,738 3,311
Discontinued operations, net of tax (4) 7,188 184,953 (563) -
Income (loss) before cumulative effect of accounting change (18,726) 151,275 2,175 3,311
Cumulative effect of accounting change, net of tax (3) (190,468) - 1,392 2,008
Net income (loss) (3) (4) (209,194) 151,275 3,567 5,319
Earnings Per Share:
Basic:
Income (loss) from continuing operations (1.00) (1.29) 0.10 0.12
Discontinued operations, net of tax 0.28 7.08 (0.02) -
Income (loss) before cumulative effect of accounting change (0.72) 5.79 0.08 0.12
Net income (loss) (8.10) 5.79 0.14 0.20
Diluted:
Income (loss) from continuing operations (1.00) (1.29) 0.10 0.12
Discontinued operations, net of tax 0.28 7.08 (0.02) -
Income (loss) before cumulative effect of accounting change (0.72) 5.79 0.08 0.12
Net income (loss) (8.10) 5.79 0.13 0.19
Weighted average shares outstanding:
Basic 25,842 26,143 26,365 26,380
Diluted 25,842 26,143 27,483 27,432
(1) During the fourth quarter of fiscal 2003, the Company recorded a tax
benefit of $35.0 million associated with management's decision to
reverse the valuation allowance for deferred tax assets. See Note 12
for further discussion.
(2) During the second quarter of 2002, the Company also recorded
restructuring and special charges aggregating $46.1 million, of which
$6.3 million is recorded in cost of services sold and $39.8 million is
recorded in selling, general and administrative expenses. See Note 4
for further discussion.
(3) For fiscal year 2002, the Company adopted the provisions of SFAS 142
"Goodwill and Other Intangible Assets" and performed a transitional
impairment test, resulting in a non-cash charge, net of tax,for the
first quarter of 2002 of $190.5 million, with related tax benefits of
$1.4 million and $2.0 million recorded in third quarter and fourth
quarter of fiscal 2002, respectively. See Note 2 for further
discussion.
(4) During the fiscal year 2002, the Company sold its SPS business to
Accredo in accordance with the asset purchase agreement, dated January
2, 2002, with the sale completed on June 13, 2002. As such, the
Company has reflected discontinued operations, including the gain on
sale, of $7.2 million, $185.0 million and ($0.6) million in the first
quarter, second quarter and third quarter of fiscal 2002,
respectively. See Note 3 for further discussion.
F-26
GENTIVA HEALTH SERVICES, INC. AND SUBSIDIARIES
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
FOR THE THREE YEARS ENDED DECEMBER 28, 2003
(IN THOUSANDS)
ADDITIONS
BALANCE AT CHARGED TO BALANCE
BEGINNING OF COSTS AND AT END
PERIOD EXPENSES DEDUCTIONS OF PERIOD
------------ ---------- ---------- ---------
Allowance for Doubtful Accounts:
For the Year Ended December 28, 2003 $ 9,032 $ 7,684 $ (8,780) $ 7,936
For the Year Ended December 29, 2002 10,831 4,936 (6,735) 9,032
For the Year Ended December 30, 2001 18,456 5,120 (12,745) 10,831
F-27